

Reimbursement Policy:

Cardiovascular Disease Risk Assessment - Lab Benefit Program (LBM)

POLICY NUMBER	EFFECTIVE DATE:	APPROVED BY
AHS-G2050	3/01/2023	RPC (Reimbursement Policy Committee)

Reimbursement Guideline Disclaimer: We have policies in place that reflect billing or claims payment processes unique to our health plans. Current billing and claims payment policies apply to all our products, unless otherwise noted. We will inform you of new policies or changes in policies through postings to the applicable Reimbursement Policies webpages on connecticare.com. Further, we may announce additions and changes in our provider manual and/or provider newsletters which are available online and emailed to those with a current and accurate email address on file. The information presented in this policy is accurate and current as of the date of this publication.

The information provided in our policies is intended to serve only as a general reference resource for services described and is not intended to address every aspect of a reimbursement situation. Other factors affecting reimbursement may supplement, modify or, in some cases, supersede this policy. These factors may include, but are not limited to, legislative mandates, physician or other provider contracts, the member's benefit coverage documents and/or other reimbursement, and medical or drug policies. Finally, this policy may not be implemented the same way on the different electronic claims processing systems in use due to programming or other constraints; however, we strive to minimize these variations.

We follow coding edits that are based on industry sources, including, but not limited to, CPT® guidelines from the American Medical Association, specialty organizations, and CMS including NCCI and MUE. In coding scenarios where there appears to be conflicts between sources, we will apply the edits we determine are appropriate. We use industry-standard claims editing software products when making decisions about appropriate claim editing practices. Upon request, we will provide an explanation of how we handle specific coding issues. If appropriate coding/billing guidelines or current reimbursement policies are not followed, we may deny the claim and/or recoup claim payment.

[POLICY DESCRIPTION](#) | [INDICATIONS AND/OR LIMITATIONS OF COVERAGE](#) | [DEFINITIONS](#) | [SCIENTIFIC BACKGROUND](#) | [GUIDELINES AND RECOMMENDATIONS](#) | [APPLICABLE STATE AND FEDERAL REGULATIONS](#) | [APPLICABLE CPT/HCPCS PROCEDURE CODES](#) | [EVIDENCE-BASED SCIENTIFIC REFERENCES](#) | [REVISION HISTORY](#)

Policy Description:

Cardiovascular risk assessment comprises the means and processes to predict the probability of developing a cardiovascular disease. These are a group of tests and health factors that have been proven to indicate a person's chance of having a cardiovascular event such as a heart attack or stroke.

Tests typically used to assess cardiovascular risk include lipid profiles or panels, biomarkers, and cardiovascular risk panels.

Terms such as male and female are used when necessary to refer to sex assigned at birth.

Indications and/or Limitations of Coverage:

Application of coverage criteria is dependent upon an individual's benefit coverage at the time of the request. Specifications pertaining to Medicare and Medicaid can be found in the "Applicable State and Federal Regulations" section of this policy document.

- 1) For individuals 18 years of age or older, lipid panel testing (see Note 1) **MEETS COVERAGE CRITERIA** under **any** of the following conditions:
 - a) To screen for cardiovascular disease (CVD) risk:
 - i) Every 4 years for individuals ages 18 to 79 years.
 - ii) Annually for individuals at increased risk for cardiovascular disease (as defined by 2013 ACC/AHA Pooled Cohort Equations (PCEs) to calculate 10-year risk of CVD events [see Note 2]).

Reimbursement Policy:

Cardiovascular Disease Risk Assessment - Lab Benefit Program (LBM)

- b) Annually for individuals at an increased risk of dyslipidemia due to **any** of the following conditions:
 - i) Obesity or metabolic syndrome
 - ii) Nephrotic syndrome
 - iii) Hypothyroidism
 - iv) Hyperthyroidism
 - v) Pancreatitis
 - vi) Diabetes
 - vii) Chronic kidney disease
 - viii) Cushing syndrome
 - ix) Pregnancy
 - x) Cholestatic liver disease
 - xi) Lipid metabolism disorders, such as Gaucher disease in adults
 - c) For individuals who are about to begin or who are currently receiving statin therapy, at the following intervals:
 - i) To establish baseline levels before initiating statin therapy.
 - ii) Every four to twelve weeks after initiation or change of therapy.
 - iii) Annually when no medication changes have occurred.
 - d) Annually for individuals on a long-term drug therapy that requires lipid monitoring (e.g., Accutane, anti-psychotics).
 - e) For HIV positive individuals who are about to begin or who are currently receiving antiretroviral therapy (ART), at the following intervals:
 - i) To establish baseline levels before initiating ART.
 - ii) Every one to three months after initiation or change of therapy.
 - iii) Every six to twelve months when no medication changes have occurred.
- 2) Measurement of apolipoprotein B (apoB) **MEETS COVERAGE CRITERIA** for **any** of the following situations:
- a) For individuals with hypertriglyceridemia.
 - b) For individuals with diabetes mellitus.
 - c) For individuals with obesity or metabolic syndrome.
 - d) For individuals with other dyslipidemias (such as very low LDL-C).
 - e) For individuals who are on lipid therapy.
 - f) For individuals who are suspected to have familial dysbetalipoproteinemia or familial combined hyperlipidemia.

Reimbursement Policy:

Cardiovascular Disease Risk Assessment - Lab Benefit Program (LBM)

- 3) Measurement of lipoprotein a (Lp(a)) once per lifetime (with measurement occurring when the individual is 18 years of age or older) **MEETS COVERAGE CRITERIA**.
- 4) For individuals for whom a risk-based treatment decision is uncertain (after quantitative risk assessment using ACC/AHA PCEs to calculate 10-year risk of CVD events [see Note 2]), testing for C-reactive protein with the high-sensitivity method (hs-CRP) **MEETS COVERAGE CRITERIA** at the following frequency:
 - a) One test for initial screening.
 - b) If the initial screen was abnormal, confirmatory testing no sooner than two weeks after the initial test.
 - c) Annual screening for those with elevated hs-CRP that has been confirmed.

The following does not meet coverage criteria due to a lack of available published scientific literature confirming that the test(s) is/are required and beneficial for the diagnosis and treatment of an individual's illness.

- 5) The following testing for CRP **DOES NOT MEET COVERAGE CRITERIA**:
 - a) Hs-CRP testing for all other cardiovascular disease risk assessments not described above.
 - b) Conventional CRP testing for cardiovascular disease risk assessment.
- 6) For CVD risk assessment and stratification in the outpatient setting, measurement of high-sensitivity cardiac troponin T (hs-cTnT) **DOES NOT MEET COVERAGE CRITERIA**.
- 7) For CVD risk assessment screening, evaluation, and management, homocysteine testing **DOES NOT MEET COVERAGE CRITERIA**.
- 8) For CVD risk assessment, measurement of novel lipid and non-lipid biomarkers (e.g., apolipoprotein AI, apolipoprotein E, B-type natriuretic peptide, cystatin C, fibrinogen, leptin, LDL subclass, HDL subclass) **DOES NOT MEET COVERAGE CRITERIA**.
- 9) Other than simple lipid panels (see Note 1), CVD risk panels, such as Boston Heart Cholesterol Balance, consisting of multiple individual biomarkers intended to assess CVD **DO NOT MEET COVERAGE CRITERIA**.
- 10) For CVD risk assessment, measurement of serum intermediate density lipoproteins **DOES NOT MEET COVERAGE CRITERIA**.
- 11) For CVD risk assessment, measurement of lipoprotein-associated phospholipase A2 (Lp-PLA2) **DOES NOT MEET COVERAGE CRITERIA**.
- 12) For all situations, measurement of long-chain omega-3 fatty acids in red blood cell membranes, **DOES NOT MEET COVERAGE CRITERIA**.
- 13) All other tests for assessing CVD risk **DO NOT MEET COVERAGE CRITERIA**.

Reimbursement Policy:

Cardiovascular Disease Risk Assessment - Lab Benefit Program (LBM)

Note 1:

A simple lipid panel is generally composed of the following lipid markers:

- Total cholesterol
- HDL cholesterol
- LDL cholesterol
- Triglycerides

Certain calculated ratios, such as the total/HDL cholesterol may also be reported as part of a simple lipid panel.

Other types of lipid testing (i.e., apolipoproteins, lipid particle number or particle size, lipoprotein [a]) are not considered to be components of a simple lipid profile.

Note 2:

2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk:¹

Risk factors include gender, age, race, smoking, hypertension, diabetes, total cholesterol, high- and low-density lipoprotein cholesterol. A race- and sex-specific PCE ASCVD Risk Estimator is available at:

https://tools.acc.org/ldl/ascvd_risk_estimator/index.html#!/calculate/estimator/.

The 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol affirms that “the PCE is a powerful tool to predict population risk, but it has limitations when applied to individuals.” Hence a clinician-patient risk discussion can individualize risk status based on PCE, but with the inclusion of additional risk-enhancing factors. These additional factors may include:

- A family history of premature atherosclerotic cardiovascular disease (ASCVD) (males, age <55 y; females, age <65 y)
- Primary hypercholesterolemia (LDL-C, 160–189 mg/dL [4.1–4.8 mmol/L]; non-HDL-C 190–219 mg/dL [4.9–5.6 mmol/L])
- Metabolic syndrome (increased waist circumference, elevated triglycerides [>150 mg/dL], elevated blood pressure, elevated glucose, and low HDL-C [<40 mg/dL in men; <50 in women mg/dL] are factors; tally of 3 makes the diagnosis)
- Chronic kidney disease (eGFR 15–59 mL/min/1.73 m² with or without albuminuria; not treated with dialysis or kidney transplantation)
- Chronic inflammatory conditions such as psoriasis, RA, or HIV/AIDS
- History of premature menopause (before age 40 y) and history of pregnancy-associated conditions that increase later ASCVD risk such as preeclampsia
- High-risk race/ethnicities (eg, South Asian ancestry)
- Lipid/biomarkers: Associated with increased ASCVD risk
- Persistently elevated, primary hypertriglyceridemia (≥ 175 mg/dL)
- Elevated high-sensitivity C-reactive protein (≥ 2.0 mg/L)
- Elevated Lp(a): A relative indication for its measurement is family history of premature ASCVD. An Lp(a) ≥ 50 mg/dL or ≥ 125 nmol/L constitutes a risk-enhancing factor especially at higher levels of Lp(a)
- Elevated apoB ≥ 130 mg/dL: A relative indication for its measurement would be triglyceride ≥ 200 mg/dL. A level ≥ 130 mg/dL corresponds to an LDL-C ≥ 160 mg/dL and constitutes a risk-enhancing factor
- ABI <0.9

Reimbursement Policy:

Cardiovascular Disease Risk Assessment - Lab Benefit Program (LBM)

Definitions:

Term	Definition
AA	Arachidonic acid
AACE	American Association of Clinical Endocrinologists
AACVPR	American Association of Cardiovascular and Pulmonary Rehabilitation
AAPA	American Academy of Physician Assistants
ABC	Association of Black Cardiologists
ABI	Ankle-brachial index
ACC	American College of Cardiology
ACCF	American College of Cardiology Foundation
ACE	American College of Endocrinology
ACPM	American College of Preventive Medicine
ADA	American Diabetes Association
ADMA	Asymmetric dimethylarginine
AGS	American Geriatrics Society
AHA	American Heart Association
Anti-CCP	Anti-cyclic citrullinated peptide
APhA	American Pharmacists Association
Apo A-I	Apolipoprotein A-I
Apo B	Apolipoprotein B
Apo C-III	Apolipoprotein C-III
Apo E	Apolipoprotein E
APs	Antipsychotics
ART	Antiretroviral therapy
ASCP	American Society for Clinical Pathology
ASCVD	Atherosclerotic cardiovascular disease
ASH	American Society of Hypertension
ASPC	American Society for Preventive Cardiology
BMI	Body mass index
BNP	Brain natriuretic peptide
CAC	Coronary artery calcium

Reimbursement Policy:

Cardiovascular Disease Risk Assessment - Lab Benefit Program (LBM)

Term	Definition
CAD	Coronary artery disease
CCS	Canadian Cardiovascular Society
CDC	Centers for Disease Control and Prevention
CHARGE	Cohorts for Heart and Aging Research in Genomic Epidemiology
CHD	Coronary heart disease
CIMT	Carotid intima media thickness
CK	Creatine kinase
CKD	Chronic kidney disease
CRP	C-reactive protein
cTnI	Cardiac troponin I
cTnT	Cardiac troponin T
CVD	Cardiovascular disease
DHA	Docosahexaenoic acid
DM	Diabetes mellitus
DoD	Department of Defense
DPA	Docosapentaenoic acid
EACPR	European Association for Cardiovascular Prevention & Rehabilitation
EAS	European Atherosclerosis Society
EASD	European Association for the Study of Diabetes
EEG	Electroencephalography
ELISA	Enzyme-linked immunosorbent assay
EPA	Eicosapentaenoic acid
ES	Endocrine Society
ESC	European Society of Cardiology
FDA	Food and Drug Administration
FH	Familial hypercholesterolemia
Fix	Family history
GDMT	Guideline-directed medical therapy
GFR	Glomerular filtration rate
GGT	Gamma-glutamyltransferase
GlycA	Glycoprotein acetyls

Reimbursement Policy:

Cardiovascular Disease Risk Assessment - Lab Benefit Program (LBM)

Term	Definition
HDL	High-density lipoprotein
HDL-C	High-density lipoprotein cholesterol
HF	Heart failure
HIV	Human immunodeficiency virus
HRs	Hazard ratios
hs-CRP	High-sensitivity C-reactive protein
hs-cTnI	High-sensitivity cardiac troponin i
hs-cTnT	High-sensitivity cardiac troponin t
IDL	Intermediate density lipoproteins
LDL	Low-density lipoprotein
LDL cholesterol	Low-density lipoprotein cholesterol
LDL-C	Low-density lipoprotein cholesterol
LDT	Laboratory developed test
LMBP	Laboratory Medicine Best Practices
Lp(a)	Lipoprotein A
LPA	Apolipoprotein(a) locus
Lp-PLA2	Lipoprotein-associated Phospholipase A2
LSP	Lipids Standardization Program
MACE	Major adverse cardiovascular event
NICE	National Institute for Health and Care Excellence
NLA	National Lipid Association
NMA	National Medical Association
Non-HDL-C	Non-high-density lipoprotein cholesterol
NT-proBNP	Amino-terminal pro-B-type natriuretic peptide
PAD	Peripheral artery disease
PCEs	Pooled cohort equations
PCNA	Preventive Cardiovascular Nurses Association
proBNP	Pro-B-type natriuretic peptide
RR	Risk ratio
sdLDL	Small dense low-density lipoprotein
SDMA	Symmetric dimethylarginine

Reimbursement Policy:

Cardiovascular Disease Risk Assessment - Lab Benefit Program (LBM)

Term	Definition
SIGN	Scottish Intercollegiate Guidelines Network
SMC™	Single Molecule Counting
T1DM	Type 1 diabetes mellitus
T2DM	Type 2 diabetes mellitus
TC	Total cholesterol
TG	Triglyceride
USPSTF	U.S. Preventive Services Task Force
VA	Veterans Affairs
VLDL	Very low-density lipoprotein

Scientific Background:

Statistics show that cardiovascular disease (including coronary heart disease, stroke, and hypertension) is America's leading health problem, and the leading cause of death. According to the 2025 update of the heart disease and stroke statistics report released by the American Heart Association:²

- Approximately 127.9 million people in this country suffer from some form of cardiovascular disease (encompassing coronary heart disease, heart failure, hypertension, and stroke).
- The direct and indirect costs of total cardiovascular disease are about \$417.9 billion and increasing every year.
- An estimated 122.4 million U.S. adults have hypertension, and 29.3 million have diabetes.
- Heart disease remains the number one cause of death in the U.S.
- On average, someone in the U.S. dies of a stroke every 3 minutes and 14 seconds.
- Women have a higher lifetime risk of stroke than men.
- Approximately 11.5 percent of U.S. adults smoke cigarettes “some days” or “every day.”

Cardiovascular Risk Assessment

Traditionally, the most important indicators for cardiac risk are those of a person's health history. These include factors such as family history, age, weight, exercise, and cigarette smoking status.³

Tests typically used to assess cardiovascular risk include:

1. Lipid profile or panel, which is the most important blood test for cardiac risk assessment
2. Biomarkers
3. Cardiovascular Risk Panels

Reimbursement Policy:

Cardiovascular Disease Risk Assessment - Lab Benefit Program (LBM)

Lipid Profile or Panel

A lipid profile or lipid panel is a panel of blood tests that serves as an initial broad medical screening tool for abnormalities in lipids, such as cholesterol and triglycerides. The results of this test can identify certain genetic diseases and can determine approximate risks for cardiovascular disease and other diseases. The lipid profile typically includes measurements of low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglycerides, and total cholesterol. Using these values, a laboratory may also calculate the very LDL (VLDL) and total cholesterol/HDL cholesterol ratio.⁴

Biomarkers

Traditional risk algorithms may miss up to 20% of cardiovascular disease (CVD) events.⁵ Numerous biomarkers have been proposed as potential risk markers for CVD. These biomarkers include but are not limited to several apolipoproteins (A, B, AI, E, LDL, HDL), B-type natriuretic peptide, and C-reactive protein. These biomarkers have been proposed as an alternative or addition for risk stratification in CVD or as treatment targets for lipid-lowering therapy.⁶⁻⁸ However, even the most promising biomarkers have only demonstrated modest associations and predictive ability.

Antonopoulos, et al. (2022) investigated the added prognostic value of biomarkers of vascular inflammation for stable patients without known coronary heart disease on top of clinical risk factors. The biomarkers—"C-reactive protein, interleukin-6 and tumor necrosis factor- α , arterial positron emission tomography/computed tomography and coronary computed tomography angiography-derived biomarkers of vascular inflammation, including anatomical high-risk plaque features and perivascular fat imaging"—were evaluated against the main endpoint of the difference in c-index (Δ [c-index]) with the use of inflammatory biomarkers for major adverse cardiovascular events (MACEs) and mortality, finding that the "Biomarkers of vascular inflammation provided added prognostic value for the composite endpoint and for MACEs only (pooled estimate for Δ [c-index] 2.9, 95% CI: 1.7-4.1 and 3.1, 95% CI: 1.8-4.5, respectively)." Coronary computed tomography angiography-related biomarkers are noteworthy as they produced the highest added prognostic benefit for MACEs, the biomarkers of which included "high-risk plaques 5.8%, 95% CI: 0.6 to 11.0, and perivascular adipose tissue (on top of coronary atherosclerosis extent and high-risk plaques): 8.2%, 95% CI: 4.0 to 12.5)." Though this may appear to be the case, the study remarked that the net clinical benefit and cost-effectiveness of using these biomarkers are still underreported and understudied.⁹

Since low-grade inflammation has been linked to early development of cardiovascular disease in the young, Chiesa, et al. (2022) evaluated whether circulating levels of glycoprotein acetyls (GlycA) were better able to predict the development of adverse cardiovascular disease risk profiles when compared with the more commonly used biomarker high-sensitivity CRP (C-reactive protein). Using data from a total of 3306 adolescents and young adults from the Avon Longitudinal Study of Parents and Children (mean age, 15.4 ± 0.3 ; $n=1750$) and Cardiovascular Risk in Young Finns Study (mean age, 32.1 ± 5.0 ; $n=1556$), the authors found that not only did "GlycA showed greater within-subject correlation over 9-to-10-year follow-up [for hypertension and metabolic syndrome] in both cohorts compared with CRP, particularly in the younger adolescent group ($r=0.36$ versus 0.07)," but GlycA was associated with multiple lifestyle-related cardiovascular disease risk factors, cardiometabolic risk factor burden, and vascular dysfunction. Moreover, in both cohorts, "only GlycA predicted future risk of both hypertension (risk ratio [RR], ≈ 1.1 per z-score increase for both cohorts) and metabolic syndrome (RR, ≈ 1.2 – 1.3 per z-score increase for both cohorts) in 9-to-10-year follow-up," suggesting that GlycA "may capture distinct sources of inflammation in the young and may provide a more sensitive measure than CRP for detecting early cardiovascular risk."¹⁰

Reimbursement Policy:

Cardiovascular Disease Risk Assessment - Lab Benefit Program (LBM)

Apolipoprotein B (Apo B)

Apolipoprotein B is a major protein in the construction and regulation of lipids. There are two forms of Apo B, Apo B-48 and Apo B-100. Apo B-100 is the major protein found in LDL and VLDL. Each LDL particle has one molecule of Apo B-100 per particle. Therefore, the Apo B concentration may represent the amount of LDL well.⁸ Increased levels of Apo B have been associated with atherosclerosis development in several large-scale studies; however, Apo B levels have yet to become routinely measured in clinical practice.^{11,12}

Researchers have hypothesized that lowering Apo B levels in young or middle-aged individuals will reduce the number of atherosclerosis cases later in life.¹³ Further, atherosclerotic changes in retinal arteries have been associated with coronary artery disease (CAD) as well as Apo B, TG, TC, and LDL-C levels.¹⁴ Lamprea-Montealegre, et al. (2020) have analyzed data from 9270 participants with chronic kidney disease to determine if triglyceride-rich lipoproteins contribute to a greater CVD risk in this population; it was determined that increased Apo B along with other triglyceride and cholesterol-related concentrations were associated with an increased risk for atherosclerotic CVD risk in chronic kidney disease patients. A second study (n=8570) has researched the relationship between Apo B levels relative to LDL-C and non-LDL-C, as well as how these levels affect subclinical atherosclerotic cardiovascular disease (ASCVD).¹⁶ Results showed that higher Apo B levels were associated with an increase in coronary artery calcium (CAC) levels among adults older than 45 years who were not taking statins, “but provided only modest additional predictive value of Apo B for CAC prevalence, incidence, or progression beyond LDL-C or non-HDL-C.”¹⁶ An equation to predict major cardiovascular events based on Apo B levels has even been developed, and when studied, this equation showed major cardiovascular event “risk prediction comparable to directly-measured Apo B in high risk patients with previous coronary heart disease.”¹⁷

In 2019, European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) published guidelines for the management of dyslipidaemias. These guidelines stated that “ApoB analysis is recommended for risk assessment, particularly in people with high TG [triglycerides], Diabetes mellitus (DM), obesity or metabolic syndrome, or very low LDL-C.”¹⁸ The ESC and EAS justify these recommendations by stating that the measurement of LDL-C levels in patients with dyslipidaemia may be inaccurate due to high DM or TG levels. “Because Apo B provides an accurate estimate of the total concentration of atherogenic particles under all circumstances, it is the preferred measurement to further refine the estimate of ASCVD risk that is modifiable by lipid-lowering therapy.”¹⁸

Apolipoprotein A-I (Apo-A-I)

Apolipoprotein A-I is a lipid-binding protein which comprises HDL molecules. HDL contains two associated apolipoproteins, A-I and A-II, and together they are the primary components of the HDL molecules. Due to Apo A-I's role as a primary structural protein for HDL, it significantly factors into the density ranges of HDL, which ultimately contribute to their overall measurement.⁸

Direct measurement of Apo A-I has been proposed as more accurate than the traditional use of HDL level. Low levels of Apo A-I may be associated with an increased risk for CVD. Testing for apo A-I is often performed with apolipoprotein B and reported as a ratio (Apo B: apo A-I), thus providing a measure of atherogenic to antiatherogenic lipoprotein particles.¹⁹

Apolipoprotein E (Apo E)

Apolipoprotein E is the primary apolipoprotein found in VLDLs and chylomicrons. Apo E is essential in the metabolism of cholesterol and triglycerides and helps to clear chylomicrons and VLDL. Apo E polymorphisms have functional effects on lipoprotein metabolism. Some Apo E genotypes are more atherogenic than others, and their measurement could provide additional information of risk of CAD.⁸

Reimbursement Policy:

Cardiovascular Disease Risk Assessment - Lab Benefit Program (LBM)

B-type or Brain Natriuretic Peptide (BNP)

Brain Natriuretic Peptide is a hormone released by the ventricles of the heart when pressure to the cardiac muscles increases or there is volume overload. BNP is now an established biochemical marker for heart failure, as the level of BNP in plasma increases proportionally based on disease severity.²⁰ Further, BNP has been accepted as an “independent surrogate marker of rehospitalization and death” for heart disease,²¹ and exhibits both diagnostic and prognostic capabilities.²²

While BNP has shown great promise for diagnostic congestive heart failure purposes, a BNP guided heart failure treatment strategy seems to be controversial; some report that this type of treatment has led to greater health-related costs and does not increase patient outcomes.²³ Still, many drugs, such as beta blockers, amiodarone, spironolactone, and angiotensin converting enzyme inhibitors, have been beneficial in reduction of circulating BNP during the management of chronic heart failure.²¹ A major limitation of BNP is that a wide range of values are observed in patients with and without heart failure; for example, obese individuals tend to have lower levels of this hormone than healthy individuals.²⁴

Januzzi, et al. (2019) used data from the GUIDing Evidence-Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) trial to develop a greater understanding of the prognostic capabilities of amino-terminal pro-BNP (NT-proBNP) following heart failure. A total of 638 individuals participated in the study. The authors concluded that “Patients with heart failure with reduced ejection fraction whose NT-proBNP levels decreased to $\leq 1,000$ pg/ml during GDMT [guideline-directed medical therapy] had better outcomes.”²⁵ These results highlight the potential for NT-proBNP to be used as a prognostic tool following heart failure.

High-Density Lipoprotein (HDL)

Apart from apolipoprotein content (AI and AII), HDL can be classified by size (small and large), by density (HDL2, HDL3), and by electrical charge (pre-beta, alpha and pre-alpha). There has been substantial interest in evaluating whether HDL subclass testing can be used to provide additional information on cardiovascular risk compared to HDL alone. HDL levels have been noted to be inversely related to CVD risk and possibly even protective against CVD. However, there are still many questions about the relationship between HDL and CVD risk, such as whether HDL levels are causative of lower CVD risk.^{8,26}

Low-Density Lipoprotein (LDL)

Low-Density Lipoprotein proteins are a significant risk factor in predicting atherosclerosis. The mechanism of how LDL subclass particles impact risk of CVD has not been determined although many mechanisms have been proposed. Even though LDL cholesterol levels may be normal, an elevation of small, dense LDL particles may be associated with CVD. One theory is that the small LDL particles can be more easily deposited into the intima, lead to atherosclerosis, and eventually CVD. Another is that LDL particles may upregulate the angiotensin II receptor, thereby promoting atherosclerosis.⁸

Lipoprotein(a)

Lipoprotein(a) (Lp[a]) is a low-density lipoprotein and has been determined to have atherogenic potential. Lp(a) has been proposed as an independent risk factor for CAD. Although research has shown it accumulates in atherosclerotic lesions, the actual process remains unclear. Serum levels of Lp(a) are highly determined by genetic polymorphisms, and the 90th percentile of Lp(a) levels was estimated at about 39 mg/dL. The overall degree of risk associated with Lp(a) levels appears to be modest, and the degree of risk may be mediated by other factors such as LDL levels and/or hormonal status. The standard method for measuring Lp(a) is density gradient ultracentrifugation. Although enzyme-linked immunosorbent assay (ELISA) techniques are available; they are unable to distinguish between Apo(a) isoforms, leading to inaccurate results.⁷ Lp(a) may have prognostic value in certain situations, such as in individuals with hypercholesterolemia.²⁷

Reimbursement Policy:

Cardiovascular Disease Risk Assessment - Lab Benefit Program (LBM)

A study focusing on the possible role of Lp(a) in CVD was performed by Willeit, et al. (2018); 26069 subjects were analyzed, and the authors found a linear relationship between elevated Lp(a) levels and CVD risk at a baseline of ≥ 30 mg/dL and an on statin level of ≥ 50 mg/dL. The baseline hazard ratios were 1.13 and 1.36 for 30-50 mg/dL and > 50 mg/dL respectively, and the hazard ratios for patients on statins were 1.08 and 1.42 respectively.²⁸

Mehta, et al. (2020) investigated “independent and joint associations of Lp(a) and FHx [family history of coronary heart disease] with atherosclerotic cardiovascular disease (ASCVD) and CHD [coronary heart disease] among asymptomatic subjects.” A total of 12149 patients were included and observed over 21 years, with Lp(a) levels measured at the first visit and remeasured at the fourth visit, nine years later, to confirm. The median age of this cohort was 54 years, and 44% of these patients had FHx. A total of 3114 ASCVD events were observed. Both FHx and elevated Lp(a) were independently associated with ASCVD, with a hazard ratio of 1.17 for FHx and a hazard ratio of 1.25 for elevated Lp(a). Patients with both FHx and elevated Lp(a) were found to have a hazard ratio of 1.43. Similar findings were found for CHD. The authors also noted that ASCVD and CHD risk reclassification and discrimination indices had improved accuracy with both FHx and Lp(a) included. The authors concluded that “elevated plasma Lp(a) and FHx have independent and additive joint associations with cardiovascular risk and may be useful concurrently for guiding primary prevention therapy decisions.”²⁹

Cystatin C

Cystatin C is a protease inhibitor protein that plays a role in inflammation and obesity. Serum testing has been proposed to diagnose impaired kidney function, which in turn may be a risk factor for CHD.³⁰ There is no published literature proving the effectiveness of Cystatin C as a biomarker for predicting cardiovascular risk and other confounding factors such as inflammation levels still need to be parsed out from Cystatin C. Overall, Cystatin C is not routinely used as a CVD biomarker.³¹

Fibrinogen

Fibrinogen is a circulating glycoprotein that plays an important role in platelet aggregation and blood viscosity. Fibrinogen has been suggested as a possible indicator of inflammation that accompanies atherosclerosis. The independent predictive power, impact on management strategies, and clinical utility of fibrinogen measurement have shown conflicting results. One study of 150000 subjects demonstrated a log-linear relationship of fibrinogen and cardiovascular events, but another study of 90000 subjects did not find a relationship; therefore further research is required.³ A recent study has reported that higher fibrinogen levels increased the risk of a stroke in large arteries or small vessels but decreased the risk of cardioembolic stroke.³²

Pieters, et al. (2020) investigated the contribution of fibrinogen, as well as other biomarkers, on CVD mortality. A total of 4487 patients were evaluated over a period of 14 years. The authors noted that 551 patients had CVD at baseline and over the time period investigated, 321 CVD deaths occurred. Fibrinogen was found to associate (“cluster”) with C-Reactive protein only and was associated with both baseline CVD and CVD mortality at follow-up. Both fibrinogen and gamma-glutamyl transferase were found to be mediators between CVD status and all-cause mortality, as well as between CVD status and CVD mortality.³³

Leptin

Leptin is a protein secreted by fat cells and plays a role in fat metabolism. As leptin increases with obesity, it is thought to be associated with CVD. Leptin may play a role in regulating blood pressure, insulin sensitivity, inflammatory vascular responses, and more. However, a meta-analysis covering 13 studies, 4257 CVD patients, and 26710 controls indicated no significant relationship between leptin and CVD, or stroke once other cardiovascular risk factors were controlled. The authors recommend further research to evaluate the effectiveness of leptin as a predictor of CVD.^{3,34} A recent study found that, in a Chinese cohort, serum leptin levels were identified as a marker for patients with first-ever acute ischemic stroke and were also associated with stroke size and severity.³⁵

Reimbursement Policy:

Cardiovascular Disease Risk Assessment - Lab Benefit Program (LBM)

Drug Therapies Requiring Lipid Monitoring

Lipid-lowering Therapy with Statins

Statins, such as ezetimibe, are a type of drug often prescribed to lower lipid levels or cholesterol. Pignone (2024) has reported that statins may reduce CVD risk by 20 to 30%, regardless of initial LDL-C levels. Statins are also beneficial for the treatment of arterial stiffness, independent of their hypolipidemic effect; treatment with a high dosage of statins will decrease LDL-C levels and improve arterial stiffness levels.³⁷ Kongpakwattana, et al. (2019) report that the use of statin therapy in combination with non-statin lipid-modifying agents is more beneficial to reduce CVD risk than using only one treatment method.

A meta-analysis of statin trials completed by Boekholdt, et al. (2014) analyzed data from 38,153 patients. During the follow-up of only 5,387 patients, it was found that 6,286 major cardiac events occurred. Great variability was recorded in LDL-C, Apo B and non-HDL-C levels based on fixed statin levels over a one-year period. "Among trial participants treated with high-dose statin therapy, >40% did not reach an LDL-C target <70 mg/dl," suggesting that high-dose statin therapy effectiveness may depend on the individual.³⁹

Antipsychotics

Several atypical antipsychotic medications, such as risperidone, sertindole and olanzapine, have been FDA approved for the treatment of psychiatric disorders, including bipolar disorder, depression, and schizophrenia; unfortunately, these medications may lead to a plethora of side effects, including dyslipidemia, hypertension, increased CVD risk, obesity, sudden cardiac death, and insulin resistance.^{40,41} Specifically, antipsychotic-induced corrected QT prolongation may increase the risk of Torsades de Pointes (a form of polymorphic ventricular tachycardia), leading to sudden cardiac death.⁴¹ While newer antipsychotics have been improved to lessen the pro-arrhythmic impact of their predecessors, they may contribute to cardiac death in a new way: by worsening the metabolic profile.⁴² It is recommended that any individuals in need of antipsychotics seriously consider the risks of these medications before accepting this type of treatment.

A ten-year study compared the CVD risk of patients with schizophrenia taking antipsychotics with healthy controls. The overall CVD risk was 5.16% in patients with schizophrenia, and 3.02% in the healthy control group; further, risk scores were significantly higher and HDL levels were significantly lower in patients taking multiple antipsychotics.⁴³ A recent meta-analysis by Rotella, et al. (2020) aimed to identify the long-term metabolic and cardiovascular effects of antipsychotic drugs. A total of 3013 studies were screened, and 92 were used for data analysis. The researchers have found a significantly higher risk of CVD death for sertindole users compared to risperidone users and state that "Long-term cardiovascular effects of APs [antipsychotics] deserve to be studied more extensively."⁴⁴

Accutane

Accutane, also known as isotretinoin, is a synthetic vitamin A derivative and oral medication often prescribed for the treatment of severe acne; it was approved by the FDA in 1982 to treat resistant, nodular acne that has not responded to conventional therapeutic measures such as systemic antibiotics.⁴⁵ Unfortunately, isotretinoin therapy may cause various cardiac events, including congenital heart disease, atrial tachycardia, and cardiac remodeling.⁴⁶ Akcay and Yuksel (2019) have reported that isotretinoin use may have been related to the development of Kounis syndrome (acute coronary syndrome due to a reduction of blood flow to the heart) in one patient. Alan, et al. (2016) reported that isotretinoin use may have triggered premature ventricular contractions in a 33-year-old woman. Karadag, et al. (2012) completed a study comprised of 70 patients who were being treated with 0.5-1.0 mg/kg per day of isotretinoin; in each patient, heart rate, blood pressure, EEG, biochemical and hematologic parameters were all measured. "We found that isotretinoin did not affect P- and QT-wave measurement."⁴⁹

Reimbursement Policy:

Cardiovascular Disease Risk Assessment - Lab Benefit Program (LBM)

Isotretinoin may also affect serum lipid levels. Zane, et al. (2006) studied 13772 patients with acne currently receiving oral isotretinoin therapy. Results showed that 31% of isotretinoin users had high cholesterol levels, 11% had high liver transaminase levels, and 44% had high triglyceride levels.⁵⁰ In a more recent study, Lee, et al. (2016) completed a systematic review and meta-analysis from 1960-2013 which studied the effects of oral isotretinoin use. Data was only admitted if 40 mg/day of isotretinoin was used for at least four weeks. The authors stated that “This meta-analysis showed that (1) isotretinoin is associated with a statistically significant change in the mean value of several laboratory tests (white blood cell count and hepatic and lipid panels), yet (2) the mean changes across a patient group did not meet a priori criteria for high-risk and (3) the proportion of patients with laboratory abnormalities was low.”^{50,51} The authors concluded by stating that these results do not support monthly laboratory testing for patients taking standard isotretinoin doses for acne purposes.

Other Cardiovascular Markers

C-Reactive Protein (CRP)

Data from numerous studies have shown an association between elevated serum or plasma concentrations of CRP and atherosclerotic vascular disease, risk of recurrent cardiovascular events, and the incidence of initial cardiovascular events among individuals not known to have atherosclerosis.⁵²

C-Reactive Protein can be measured using either traditional assays or high-sensitivity CRP (hs-CRP) assays. Traditional assays have limited use when screening for cardiovascular disease due to their limit of detection (3-5 mg/L). On the other hand, hs-CRP assays can detect concentrations of CRP down to 0.3 mg/L and below. These hs-CRP assays are used to assess cardiovascular risk because they can detect and quantify CRP within the range normally seen in asymptomatic patients (<3 mg/L). Elevated CRP levels, either alone or in combination with other cardiovascular risk factors, have been associated with a higher risk of future cardiovascular events. Studies evaluating CRP in asymptomatic populations have shown that the baseline level of CRP predicts the long-term risk of a first myocardial infarction (MI), ischemic stroke, hypertension, peripheral vascular disease, sudden cardiac death, and all-cause mortality.⁵²

Mehta, et al. (2025) explored the evolving role of hs-CRP in assessing residual inflammatory risk in patients with ASCVD. Drawing from a broad range of clinical trials, epidemiological studies, and guideline updates, they examined how hs-CRP can inform risk stratification and therapeutic decision making particularly in individuals who have achieved LDL cholesterol goals but remain at heightened cardiovascular risk. While routine use of hs-CRP in secondary prevention is not universally endorsed, the authors argue for a more personalized approach, where hs-CRP may guide consideration of anti-inflammatory therapies to further reduce ASCVD events. Their conclusion supports integrating hs-CRP testing selectively into clinical practice to complement traditional lipid-focused strategies.⁵³

Homocysteine

Homocysteine is an amino acid that is produced by the body. Elevated levels of homocysteine may result in damage to the walls of the artery, increase the potential for thrombosis and lead to advanced atherosclerosis. Hence, elevated homocysteine levels have been demonstrated to increase the risk of CVD. However, the testing of homocysteine levels is not consistently recommended because, based on current research, the lowering of plasma homocysteine levels does not necessarily lower the risk of CVD. Further research is required to support the clinical utility of lowering homocysteine levels.⁵⁴

Intermediate Density Lipoproteins (IDL)

Intermediate Density Lipoproteins (remnant cholesterol or lipoproteins) are the cholesterol content of triglyceride-rich lipoproteins, which is composed of VLDL and IDL in the fasting state, and is a combination of VLDL, IDL, and chylomicron remnants in the nonfasting state. It can be estimated by triglyceride (TG) levels in

Reimbursement Policy:

Cardiovascular Disease Risk Assessment - Lab Benefit Program (LBM)

the absence of advanced lipoprotein testing. Elevated nonfasting plasma triglyceride is associated with increased risk for CVD.⁵⁵ Triglycerides are unlikely to directly cause CVD, thus VLDL and IDL are more commonly identified as the source of this increased risk for CVD.⁵⁶ VLDL and IDL have been shown to be proatherogenic with both proinflammatory and prothrombotic effects.⁵⁷

Genetic case studies have shown that elevated levels of remnant cholesterol are causally associated with both low-grade inflammation and CVD. Elevated levels of LDL cholesterol are associated with CVD, but not with low-grade inflammation. This indicates that elevated LDL cholesterol levels cause atherosclerosis without inflammation, whereas elevated remnant cholesterol levels lead to both atherosclerosis and inflammation.^{55,58}

Another measure which includes IDL is non-HDL-C, which is derived from the simple calculation of total cholesterol minus HDL-C. The Emerging Risk Factors Collaboration concluded that apoB and non-HDL-C predicted risk similar to directly-measured LDL-C and that fasting did not affect the hazard ratios (HRs).⁵⁹

Lipoprotein-associated Phospholipase A2 (Lp-PLA2)

Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an inflammatory enzyme expressed in atherosclerotic plaques. It has been proposed that Lp-PLA2 testing may aid in detecting CVD risk due to its association with other biomarkers, such as LDL. The rationale for Lp-PLA2 as a key inflammatory biomarker is attractive because this enzyme is produced in atherosclerotic plaques with elevated expression found in CVD patients.⁶⁰

Numerous studies evaluate Lp-PLA2 as a predictor of cardiovascular risk.⁶¹⁻⁶³ These studies demonstrate that Lp-PLA2 is an independent predictor of CVD. Preliminary clinical trials of Lp-PLA2 inhibitors showed some improvements in physiologic measures, such as reduction in hs-CRP.⁶³ However, further clinical trials of Lp-PLA2 inhibitors failed to demonstrate significant improvements in patient outcomes.⁶⁴ Although Lp-PLA2 does not appear to have any predictive power with apparently healthy individuals, it may have utility for symptomatic patients. The link between the enzyme and LDL is found in the enzyme's plasma activity, which tends to vanish with treatment.⁶⁰ De Stefano, et al. (2019) stated that Lp-PLA2 may be considered as a new vascular specific biomarker to predict CVD in a population of patients with metabolic diseases.

Long-Chain Omega-3 Fatty Acids

Omega-3 fatty acids, a specific group of polyunsaturated fatty acids containing a double bond three carbons from the methyl terminus, are main building blocks of many fats and oils. Long-chain omega 3 fatty acids ($\geq C_{20}$, LC) include eicosapentaenoic acid (EPA, 20:5 ω 3), docosapentaenoic acid (DPA, 22:5 ω 3) and docosahexaenoic acid (DHA, 22:6 ω 3) and are thought to be beneficial in the prevention of CHD.⁶⁶ Circulating blood levels of EPA and DHA are inversely and significantly associated with reduced CHD event risk.⁶⁷ Blood levels of omega-3 fatty acids may be more related to CVD benefit than the daily dose of fish oil supplements.⁶⁸ The blood EPA/arachidonic acid (AA) ratio may be a clinically relevant measurement as AA has atherogenic and thrombogenic metabolites. Although this ratio has substantial individual variability, an EPA/AA ratio >0.75 has been associated with a significantly lower number of major coronary events in a Japanese population.⁶⁹ Determination of blood omega-3 levels may help guide the appropriate use of dietary fish or omega-3 supplements in a personalized heart disease prevention strategy.

The relationship of fish and dietary omega-3 fatty acids and CVD has been investigated in numerous studies and comprehensive reviews and recommendations exist, but guidance on blood concentrations is missing. Some prospective fish oil treatment investigations report a significant reduction in CVD events, but others do not.^{69,70} A meta-analysis did not find a statistically significant relationship between omega-3 consumption and CVD mortality.⁷¹ A science advisory from the American Heart Association (AHA) stated that for individuals with prevalent CHD such as a recent MI event, treatment with omega-3 PUFA supplements is reasonable; further, for patients with prevalent heart failure without preserved left ventricular function, fish oil treatment is recommended, while treatment is not recommended for patients with DM, pre-diabetes or as a method for stroke prevention.⁷²

Reimbursement Policy:

Cardiovascular Disease Risk Assessment - Lab Benefit Program (LBM)

Troponins (I, T)

Troponins are specific biomarkers for cardiac injury and are often used to diagnose myocardial infarctions. These proteins control the calcium-mediated interaction of actin and myosin in the muscle, and the cardiac versions of these proteins are unique to the heart. There are two primary categories of tests for troponins; “sensitive or contemporary” and “high-sensitive.” The high-sensitive version is preferred due to its superior accuracy.^{73,74}

Elevated levels of troponins are proposed to predict CVD risk. Ford, et al. (2016) performed a study evaluating troponin levels in 3318 men in relation to CVD risk. A hazard ratio of 2.3 for the highest quartile of troponin (≥ 5.2 ng/L) compared to the lowest quartile (≤ 3.1 ng/L) was found. The authors also found a 5-fold reduction in coronary events when troponin levels decreased by a quarter.⁷⁵

Tang, et al. (2020) evaluated the ability of high-sensitivity cardiac troponin I (hs-cTnI) to assess cardiovascular risk and mortality. A total of 5876 patients ages 66-90 years were included. A total of 1053 deaths (321 CVD-related) occurred, within a median follow-up of 6.3 years. Patients with an elevated hs-cTnI and without history of CVD had a similar mortality risk to patients with a CVD history but without an elevated hs-cTnI. However, after adjustment, elevated hs-cTnI was found to be associated with mortality risk, by a hazard ratio of 2.38 over low hs-cTnI and no CVD. Elevated hs-cTnI was found to be independently associated with incident CVD by a hazard ratio of 3.41, ASCVD (HR = 2.02) and heart failure (HR = 6.16). The authors concluded that “Hs-cTnI improves mortality and CVD risk stratification in older adults beyond traditional risk factors and improved model discrimination more than hs-cTnT for certain outcomes.”⁷⁶

Suthahar, et al. (2020) “evaluated associations of high-sensitivity cardiac troponin-T (cTnT) with cardiovascular disease (CVD), heart failure (HF), and mortality in community-dwelling women and men.” A total of 8226 adults were included in the study. The authors detected cTnT levels in 1102 women and 2396 men. The authors found these baseline levels to be associated with a greater risk of developing CVD in women compared to men (women hazard ratio = 1.48, men hazard ratio = 1.20). Similar sex-related differences were found for HF and mortality. Women at six ng/L were also found to have significantly increased risk for CVD, HF, and mortality whereas men were only found to have significantly increased risk for CVD at the same level of cTnT.⁷⁷

Proprietary Testing

Cardiovascular Risk Panels/Profiles

Cardiovascular risk panels refer to combinations of cardiac markers that are used for the risk assessment of developing cardiovascular disease, MACEs, or ischemic cerebrovascular events. Commercially available risk panels use different combinations of lipids, inflammatory, genetic, and metabolic markers. Risk panels report the results of multiple individual tests, whereas quantitative risk scores generally use proprietary algorithms to combine the results of multiple markers into one score. The clinical utility of risk panels is lacking as the impact of results on patient management is unknown.

Examples of commercially available cardiovascular risk panels include, but are not limited to:

1. Genova Diagnostics Cardio Check™ Panel:
 - Lipid markers (LDL; total cholesterol; HDL; triglycerides; lipoprotein (a); total cholesterol/HDL ratio; triglycerides/HDL ratio)
 - Independent risk factors (hs-CRP; homocysteine)
 - Insulin
 - Sex hormone markers (testosterone, total; sex hormone binding globulin).⁷⁸
2. Cleveland HeartLab CVD Inflammation Testing Profile
 - F2-isoprostanes; oxidized LDL; hs-CRP; ADMA/SDMA; microalbumin; myeloperoxidase; Lp-PLA2 activity.⁷⁹

Reimbursement Policy:

Cardiovascular Disease Risk Assessment - Lab Benefit Program (LBM)

Guidelines and Recommendations:

American College of Cardiology (ACC) and the American Heart Association (AHA)

The 2019 ACC and AHA guidelines state that “Adults who are 40 to 75 years of age and are being evaluated for cardiovascular disease prevention should undergo 10-year atherosclerotic cardiovascular disease (ASCVD) risk estimation and have a clinician-patient risk discussion before starting on pharmacological therapy, such as antihypertensive therapy, a statin, or aspirin. In addition, assessing for other risk-enhancing factors can help guide decisions about preventive interventions in select individuals, as can coronary artery calcium scanning.”⁸⁰

Laboratory testing was not addressed in this update.

The ACC and AHA published joint guidelines on the assessment of cardiovascular risk in asymptomatic patients in 2010,⁸¹ and updated in 2013.¹

In adults between the ages of 20 and 79 who are free from CVD, the ACC/AHA state that it is reasonable to assess risk factors (smoking, hypertension, diabetes, total cholesterol, high-density lipoprotein cholesterol) every four to six years. For adults who are 40 to 79 and who are free from ASCVD, it is reasonable to estimate 10-year ASCVD risk every four to six years.”¹

The ACC/AHA also made the following recommendations on reclassification or contribution to risk assessment when high-sensitivity C-reactive protein (hs-CRP), apolipoprotein B (ApoB), glomerular filtration rate (GFR), microalbuminuria, family history, cardiorespiratory fitness, ankle-brachial index (ABI), carotid intima media thickness (CIMT), or CAC score are considered in addition to the variables that are in the traditional risk scores:

1. If, after quantitative risk assessment, a risk-based treatment decision is uncertain, assessment of one or more of the following—family history, hs-CRP, ABI or CAC may be considered to inform treatment decision making.
2. CIMT is not recommended for routine measurement in clinical practice for risk assessment for a first ASCVD event.
3. The contribution to risk assessment for a first ASCVD event using ApoB, chronic kidney disease, albuminuria, or cardiorespiratory fitness is uncertain at present.¹

The 2010 guidelines contained the following statement concerning testing for Lp-PLA2: Lipoprotein-associated phospholipase A2 might be reasonable for cardiovascular risk assessment in intermediate risk asymptomatic adults. However, the 2013 guidelines on the assessment of cardiovascular risk do not mention Lp-PLA2 testing.^{1,81}

The updated guidelines do not address arterial compliance, lipoprotein-associated phospholipase, long-chain omega-3 fatty acids, or endothelial function assessment as methods to assess initial CVD risk.^{1,81}

The ACC notes cutoffs of certain biomarkers for increased ASCVD risk, which are as follows: persistently elevated, primary hypertriglyceridemia ≥ 175 mg/dL, ≥ 2 mg/L hs-CRP, ≥ 50 mg/dL or ≥ 125 nmol Lp(a), ≥ 130 mg/dL Apo B (corresponding to >160 mg/dL LDL-C), and <0.9 ABI.^{27,82}

The ACC and AHA also released joint guidelines with the AAPA, ABC, ACPM, AGS, APhA, ASH, ASPC, NMA, and PCNA, stating that screening and management of dyslipidemia/hypercholesterolemia is recommended in adults with hypertension (defined as $>130/80$ mmHg).⁸³

Reimbursement Policy:

Cardiovascular Disease Risk Assessment - Lab Benefit Program (LBM)

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

This joint report discusses management of blood cholesterol. The report addresses treatments, populations of interest, and serum assessments of relevant cardiovascular biomarkers such as Apo B and lipoprotein A. The relevant recommendations are listed below:

The report notes that although measurement of Apo B may be “unreliable,” persistent elevation of Apo B may be considered a risk factor. The report remarks that a level of >130 mg/dL Apo B should be considered a risk-enhancing factor [of ASCVD], as it corresponds to an LDL-C level of ≥ 160 mg/dL.

The report also remarks that Lp(a) is considered a risk factor for ASCVD at levels of “ ≥ 50 mg/dL or ≥ 125 nmol/L.” However, the authors write that it should be “considered in women only in the presence of hypercholesterolemia and with the understanding that the improvement in risk prediction in adult women in a large clinical trial was minimal.”

Authors also recommend assessing “adherence and percentage response to LDL-C-lowering medications and lifestyle changes with repeat lipid measurement 4 to 12 weeks after statin initiation or dose adjustment, repeated every 3 to 12 months as needed.”

The power of these risk factors can be seen in the “pooled cohort equation”, “the single most robust tool for estimating 10-year risk in US adults 40 to 75 years of age.” These algorithms have strong representative power for larger populations. However, a notable limitation of these algorithms is that they are not as accurate for individuals. Hence a clinician-patient risk discussion can individualize risk status based on PCE, but with the inclusion of additional risk-enhancing factors. These additional factors may include:

- “A family history of premature ASCVD (males, age <55 y; females, age <65 y)
- Primary hypercholesterolemia (LDL-C, 160 – 189 mg/dL [4.1 – 4.8 mmol/L]; non-HDL-C 190 – 219 mg/dL [4.9 – 5.6 mmol/L])
- Metabolic syndrome (increased waist circumference, elevated triglycerides [>150 mg/dL], elevated blood pressure, elevated glucose, and low HDL-C [<40 mg/dL in men; <50 in women mg/dL] are factors; tally of 3 makes the diagnosis)
- Chronic kidney disease (eGFR 15 – 59 mL/min/ 1.73 m² with or without albuminuria; not treated with dialysis or kidney transplantation)
- Chronic inflammatory conditions such as psoriasis, RA, or HIV/AIDS
- History of premature menopause (before age 40 y) and history of pregnancy-associated conditions that increase later ASCVD risk such as preeclampsia
- High-risk race/ethnicities (e.g., South Asian ancestry)
- Lipid/biomarkers: Associated with increased ASCVD risk
- Persistently elevated, primary hypertriglyceridemia (≥ 175 mg/dL)
- Elevated high-sensitivity C-reactive protein (≥ 2.0 mg/L)
- Elevated Lp(a): A relative indication for its measurement is family history of premature ASCVD. An Lp(a) ≥ 50 mg/dL or ≥ 125 nmol/L constitutes a risk-enhancing factor especially at higher levels of Lp(a)
- Elevated apoB ≥ 130 mg/dL: A relative indication for its measurement would be triglyceride ≥ 200 mg/dL. A level ≥ 130 mg/dL corresponds to an LDL-C ≥ 160 mg/dL and constitutes a risk-enhancing factor
- ABI <0.9 ²⁷

Reimbursement Policy:

Cardiovascular Disease Risk Assessment - Lab Benefit Program (LBM)

American Diabetes Association (ADA)

The updated ADA Standards of Medical Care in Diabetes document also includes a section focused on cardiovascular disease and risk management. Relevant guidelines and notes are captured below.

- “Blood pressure should be measured at every routine clinical visit, or at least every 6 months. Individuals found to have elevated blood pressure without a diagnosis of hypertension (systolic blood pressure 120–129 mmHg and diastolic blood pressure <80 mmHg) should have blood pressure confirmed using multiple readings, including measurements on a separate day, to diagnose hypertension.
- “Counsel all people with hypertension and diabetes to monitor their blood pressure at home after appropriate education.”
- “In asymptomatic patients, routine screening for coronary artery disease is not recommended, as it does not improve outcomes as long as atherosclerotic cardiovascular disease risk factors are treated.
- “Consider investigations for coronary artery disease in the presence of any of the following: signs or symptoms of cardiac or associated vascular disease, including carotid bruits, transient ischemic attack, stroke, claudication, or PAD; or electrocardiogram abnormalities (e.g., Q waves).
- “Adults with diabetes are at increased risk for the development of asymptomatic cardiac structural or functional abnormalities (stage B heart failure) or symptomatic (stage C) heart failure. Consider screening adults with diabetes by measuring a natriuretic peptide (B-type natriuretic peptide [BNP] or N-terminal pro-BNP [NT-proBNP]) to facilitate prevention of stage C heart failure.
- “In asymptomatic individuals with diabetes and abnormal natriuretic peptide levels, echocardiography is recommended to identify stage B heart failure.
- “The screening of asymptomatic patients with high ASCVD risk is not recommended, in part because these high-risk patients should already be receiving intensive medical therapy—an approach that provides benefit similar to those of invasive revascularization.
- “In adults with prediabetes or diabetes not taking statins or other lipid-lowering therapy, it is reasonable to obtain a lipid profile at the time of diagnosis, at an initial medical evaluation, annually thereafter, or more frequently if indicated.”⁸⁴
- “Recently, risk scores and other cardiovascular biomarkers have been developed for risk stratification of secondary prevention patients (i.e., those who are already high risk because they have ASCVD) but are not yet in widespread use.”⁸⁵
- “The American College of Cardiology/American Heart Association ASCVD risk calculator (Risk Estimator Plus) is generally a useful tool to estimate 10-year risk of a first ASCVD event...The 10-year risk of a first ASCVD event should be assessed to better stratify ASCVD risk and help guide therapy, as described below.”⁸⁶
- “Obtain a lipid profile at initiation of statins or other lipid-lowering therapy, 4–12 weeks after initiation or a change in dose, and annually thereafter as it may help to monitor the response to therapy and inform medication adherence.”⁸⁴

Also, for children and adolescents, the following recommendations were given for dyslipidemia testing:

- “Initial lipid profile should be performed soon after diagnosis, preferably after glycemia has improved and age is ≥ 2 years. If initial LDL cholesterol is ≤ 100 mg/dL (≤ 2.6 mmol/L), subsequent testing should be performed at 9–11 years of age. Initial testing may be done with a nonfasting lipid level with confirmatory testing with a fasting lipid panel.

Reimbursement Policy:

Cardiovascular Disease Risk Assessment - Lab Benefit Program (LBM)

- If LDL cholesterol values are within the accepted risk level (<100 mg/dL [2.6 mmol/L]), a lipid profile repeated every 3 years is reasonable.”⁸⁷

National Lipid Association (NLA)

The NLA published a scientific statement for lipid measurements in the management of cardiovascular disease, and their recommendations (with evidence rating of “B” or higher) are included below:

- “It is recommended to follow up abnormal screening lipid measurements with fasting lipid measurement (Strength: IIa. Evidence: B-NR)
- LDL-C in adults ≥ 190 mg/dL (≥ 160 mg/dl in children) is recommended to be reported as possible Familial Hypercholesterolemia (Strength: I. Evidence: B-NR)
- Non-HDL-C in adults ≥ 220 mg/dL is recommended to be reported as possible inherited hyperlipidemia (Strength: I. Evidence: B-NR)
- Triglyceride concentration ≥ 500 mg/dL is recommended to be reported as severe hypertriglyceridemia (Strength: I. Evidence: B-NR)
- Lipid measurements are recommended at 3-12 months for those on a stable medication regimen (Strength: I. Evidence: B-NR)
- Lipid measurements are recommended 4-12 weeks after a change in lipid treatment (Strength: I. Evidence: B-NR)
- LDL-C measurement is recommended for screening (Strength: I. Evidence: B-NR)
- LDL-C measurement is recommended on lipid therapy (Strength: I. Evidence: B-NR)
- Non-HDL-C measurement is recommended for screening (Strength: I. Evidence: B-NR)
- Non-HDL-C measurement is recommended on lipid therapy (Strength: I. Evidence: B-NR)
- Apolipoprotein B measurement may be reasonable for initial evaluation (Strength: IIb. Evidence: B-NR)
- Apolipoprotein B measurement is reasonable on lipid therapy (Strength: IIa. Evidence: B-NR)
- Apolipoprotein B measurement is recommended to facilitate diagnosis of Familial Dysbetalipoproteinemia and Familial Combined Hyperlipidemia (Strength: IIb. Evidence: B-NR)
- Lipoprotein (a) measurement is reasonable for initial evaluation in those with premature ASCVD, family history of premature ASCVD or of elevated Lp(a), history of LDL-C >190 mg/dL or suspected FH, or those with very high ASCVD risk (Strength: IIa. Evidence: B-NR)
- Lipoprotein (a) measurement may be reasonable on lipid therapy to determine those who may benefit from PCSK9 therapy who are already on maximal dose statin therapy $\pm$ ezetimibe, whose LDL-C remains above 70 mg/dl (Strength: IIb. Evidence: B-NR)”

Wilson, et al. (2019) published a scientific statement to provide an update on the use of lipoprotein A [Lp(a)] in the clinical setting, particularly for ASCVD.

Reimbursement Policy:

Cardiovascular Disease Risk Assessment - Lab Benefit Program (LBM)

The Association lists the following recommendations for Lp(a) testing in clinical practice:

For adults over 20 years old, "Measurement of Lp(a) is **reasonable** to refine risk assessment for ASCVD events in:

- Individuals with a family history of first-degree relatives with premature ASCVD (<55 y[ears] of age in men, 65 y of age in women)
- Individuals with premature ASCVD (males aged <55 y and females aged <65 y), particularly in the absence of traditional risk factors
- Individuals with primary severe hypercholesterolemia (LDL $\geq$ 190 mg/dL) or suspected FH [familial hypercholesterolemia]
- Individuals at very high** risk of ASCVD to better define those who are more likely to benefit from PCSK9 inhibitor therapy."

**Very high risk is defined as "Individuals with a history of multiple major ASCVD events or 1 major ASCVD event and multiple high-risk conditions."

The guidelines further remark that "Measurement of Lp(a) **may be reasonable** with:

- Intermediate (7.5%–19.9%) 10-y ASCVD risk when the decision to use a statin is uncertain, to improve risk stratification in primary prevention.
- Borderline (5%–7.4%) 10-y ASCVD risk when the decision to use a statin is uncertain, to improve risk stratification in primary prevention.
- Less-than-anticipated LDL-C lowering, despite good adherence to therapy.
- A family history of elevated Lp(a).
- Calcific valvular aortic stenosis.
- Recurrent or progressive ASCVD, despite optimal lipid-lowering therapy."

Finally, the guidelines list recommendations for "youth" (<20 years old), stating that "Measurement of Lp(a) may be reasonable with:

- Clinically suspected or genetically confirmed FH.
- Individuals with a family history of first-degree relatives with premature ASCVD (<55 y of age in men, 65 y of age in women)
- An unknown cause of ischemic stroke
- A parent or sibling found to have an elevated Lp(a)."⁸⁸

A 2021 update was published, focused on practical and analytical recommendations:⁸⁹

"Highlights include the following:

2. It is acceptable to screen with nonfasting lipids.
3. Non-high-density lipoprotein HDL-cholesterol (non-HDL-C) is measured reliably in either the fasting or the nonfasting state and can effectively guide ASCVD prevention.

Reimbursement Policy:

Cardiovascular Disease Risk Assessment - Lab Benefit Program (LBM)

4. Low density lipoprotein cholesterol (LDL-C) can be estimated from total cholesterol, high density lipoprotein cholesterol (HDL-C), and triglyceride (TG) measurements. For patients with LDL-C > 100 mg/dL and TG ≤ 150 mg/dL it is reasonable to use the Friedewald formula. However, for those with TG 150-400 mg/dL the Friedewald formula for LDL-C estimation is less accurate. The Martin/Hopkins method is recommended for LDL-C estimation throughout the range of LDL-C levels and up to TG levels of 399 mg/dL. For TG levels ≥ 400 mg/dL LDL-C estimating equations are currently not recommended and newer methods are being evaluated.
5. When LDL-C or TG screening results are abnormal the clinician should consider obtaining fasting lipids.
6. Advanced lipoprotein tests using apolipoprotein B (apoB), LDL Particle Number (LDL-P) or remnant cholesterol may help to guide therapeutic decisions in select patients, but data are limited for patients already on lipid lowering therapy with low LDL-C levels. Better harmonization of advanced lipid measurement methods is needed. Lipid measurements are recommended 4-12 weeks after a change in lipid treatment. Lipid laboratory reports should denote desirable values and specifically identify extremely elevated LDL-C levels (≥ 190 mg/dL at any age or ≥ 160 mg/dL in children) as severe hypercholesterolemia. Potentially actionable abnormal lipid test results, including fasting triglycerides (TG) ≥ 500 mg/dL, should be reported as hypertriglyceridemia. Appropriate use and reporting of lipid tests should improve their utility in the management of persons at high risk for ASCVD events.”

Centers for Disease Control and Prevention (CDC)

The CDC highlights the importance of cardiovascular disease biomarkers and has developed a reference laboratory and clinical standardization program to provide reference measurements for HDL-C, LDL-C, TG and total cholesterol (TC). The accuracy of the labs that analyze these biomarkers is also monitored by the CDC.⁹⁰

The CDC notes that several health conditions increase the risk of heart disease including smoking, DM, obesity, high blood pressure, excessive alcohol use, physical inactivity, and unhealthy blood cholesterol levels. It is stated that “High blood cholesterol usually has no signs or symptoms. The only way to know whether you have high cholesterol is to get your cholesterol checked. Your health care team can do a simple blood test, called a “lipid profile,” to measure your cholesterol levels.”⁹¹

The CDC has also developed the Lipids Standardization Program (LSP). This program ensures that the measurements reported in research studies and clinical laboratories are accurate. Blinded samples traceable to the CDC Reference Laboratory are provided to participants. The samples will be measured for total cholesterol (TC), glycerides (TG), high-density lipoprotein cholesterol (HDL-C), apolipoprotein A-I (Apo A-I), and apolipoprotein B (Apo B). LSP participants report their results from the provided samples back to the CDC where these results are then analyzed; if results are accurate, those laboratories receive a certificate and are considered CDC-certified.⁹²

Centers for Disease Control and Prevention (CDC)/American Heart Association (AHA)

In 2002, the CDC and AHA held the “CDC/AHA Workshop on Inflammatory Markers and Cardiovascular Disease: Applications to Clinical and Public Health Practice” and released these recommendations in 2003. In this workshop, they looked at evidence surrounding multiple inflammatory markers and based on all considerations, they stated that “it is most reasonable to limit current assays of inflammatory markers to hs-CRP, measured twice, either fasting or nonfasting, with the average expressed in mg/L, in metabolically stable patients.” More specifically, they indicate that the two measurements of hs-CRP should optimally occur two weeks apart. If results are abnormal, hs-CRP testing should be repeated and the patient should be examined for sources of infection or inflammation. Furthermore, they provide the following recommendation specific to hs-CRP: “On the basis of the available evidence, the Writing Group recommends against screening of the entire adult population for hs-CRP as a public health measure. The Writing Group does conclude that it is reasonable to measure hs-CRP as an adjunct to the major risk factors to further assess absolute risk for coronary disease primary prevention. At the discretion of the physician, the measurement is considered optional, based on the

Reimbursement Policy:

Cardiovascular Disease Risk Assessment - Lab Benefit Program (LBM)

moderate level of evidence (Evidence Level C). In this role, hs-CRP measurement appears to be best employed to detect enhanced absolute risk in persons in whom multiple risk factor scoring projects a 10-year CHD risk in the range of 10% to 20% (Evidence Level B). However, the benefits of this strategy or any treatment based on this strategy remain uncertain. The finding of a high relative risk level of hs-CRP (>3.0 mg/L) may allow for intensification of medical therapy to further reduce risk and to motivate some patients to improve their lifestyle or comply with medications prescribed to reduce their risk. Individuals at low risk (<10% per 10 years) will be unlikely to have a high risk (>20%) identified through hs-CRP testing. Individuals at high risk (>20% risk over 10 years) or with established atherosclerotic disease generally should be treated intensively regardless of their hs-CRP levels, so the utility of hs-CRP in secondary prevention appears to be more limited.”⁹³

Centers for Medicare & Medicaid Services (CMS)

In 2005, CMS published national coverage determination that discuss appropriate frequency of monitoring for individuals receiving long-term pharmacologic treatments that may affect lipid levels and thus may affect that individuals risk of developing CVD. The indications and limitations of coverage state:

“When monitoring long term anti-lipid dietary or pharmacologic therapy and when following patients with borderline high total or LDL cholesterol levels, it is reasonable to perform the lipid panel annually. A lipid panel at a yearly interval will usually be adequate while measurement of the serum total cholesterol or a measured LDL should suffice for interim visits if the patient does not have hypertriglyceridemia.”⁹⁴

“Any one component of the panel or a measured LDL may be medically necessary up to six times the first year for monitoring dietary or pharmacologic therapy. More frequent total cholesterol HDL cholesterol, LDL cholesterol and triglyceride testing may be indicated for marked elevations or for changes to anti-lipid therapy due to inadequate initial patient response to dietary or pharmacologic therapy. The LDL cholesterol or total cholesterol may be measured three times yearly after treatment goals have been achieved.”⁹⁴

“If no dietary or pharmacological therapy is advised, monitoring is not necessary.”⁹⁴

American Heart Association (AHA)

In 2022, the AHA published a scientific statement to highlight the history, biology, pathophysiology, and emerging clinical evidence in the lipoprotein a (Lp[a]) field, where they addressed the “key knowledge gaps and future directions required to mitigate the atherosclerotic cardiovascular disease risk attributable to elevated Lp(a) levels.” In this statement, they noted that “levels of Lp(a) have not been shown to substantially change across the life course, although some variability occurs, as documented by intraindividual temporal variability in serial measurements from placebo-treated subjects in clinical trials.” They also note that “various organizations have proposed to obtain a level once in every adult.”⁹⁵

American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE)

The 2017 AACE and ACE Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease recommend:

- Screening guidelines for dyslipidemia vary by age group;
- Although ASCVD risk in young adults is low, adults older than 20 years should be evaluated for dyslipidemia every five years as part of a global risk assessment
- Middle-aged individuals (Men 45-65 years, Women 55-65 years) should be screened for dyslipidemia at least every one to two years.

Reimbursement Policy:

Cardiovascular Disease Risk Assessment - Lab Benefit Program (LBM)

- All individuals with diabetes should be screened with a lipid profile at the time of diagnosis and annually thereafter. Some individuals with diabetes can be screened less frequently based on clinical considerations
- Annual screen for dyslipidemia for adults over 65 is recommended
- In children at risk for FH (e.g., family history of premature cardiovascular disease or elevated cholesterol), screening should be at three years of age, between 9 and 11, and at age 18
- Screen adolescents older than 16 years every five years or more frequently if they have ASCVD risk factors, have overweight or obesity, have other elements of the insulin resistance syndrome, or have a family history of premature ASCVD
- Direct measurement of LDL-C should be used to assess LDL-C in certain high-risk individuals, such as those with fasting TG concentrations greater than 250 mg/dL or those with diabetes or known vascular disease
- Apolipoproteins, Apo B and/or an Apo B/Apo A1 ratio calculation and evaluation may be useful in at risk individuals.
- hs-CRP is recommended to stratify ASCVD risk in individuals with a standard risk assessment that is borderline, or in those with an intermediate or higher risk with an LDL-C concentration <130 mg/dL.
- Lp-PLA2 measurement, is recommended when it is necessary to further stratify an individual's ASCVD risk, especially in the presence of hs-CRP elevations.
- The routine measurement of homocysteine, uric acid, plasminogen activator inhibitor-1, or other inflammatory markers is not recommended because the benefit of doing so is not sufficiently proven.
- Coronary artery calcification measurement has been shown to be of high predictive value and is useful in refining risk stratification
- CIMT may be considered to refine risk stratification.⁹⁶

The AACE/ACE published an updated algorithm in 2020. This algorithm focuses on “management of dyslipidemia and prevention of cardiovascular disease” and “complements” the above guidelines but includes information not available in 2017. Their relevant recommendations are listed below:

The guideline lists Apo B, LDL, Lp(a), and hs-CRP as biomarkers that may be “considered” in assessment of ASCVD risk for patients. The guideline also remarks that “measurement of Apo B is useful in assessing the success of lipid-lowering therapy, since Apo B may remain above goal after achieving the LDL-C goal.” Apo B is listed as a component of treatment goals, alongside LDL-C, non-HDL-C, and TG [triglycerides].

The guideline recommends “considering” measurement of Lp(a) (lipoprotein A) in the following settings:

- “All patients with clinical ASCVD, especially premature or recurrent ASCVD despite LDL-C lowering;
- Individuals with a family history of premature ASCVD and/or increased Lp(a);
- Individuals with South Asian or African ancestry, especially with a family history of ASCVD or increased Lp(a);
- Individuals with a 10-year ASCVD risk $\geq 10\%$ (primary prevention setting), in order to stratify risk;
- Patients with a personal or family history of aortic valve stenosis;

Reimbursement Policy:

Cardiovascular Disease Risk Assessment - Lab Benefit Program (LBM)

- Patients with refractory elevations of LDL-C despite aggressive LDL-C-lowering therapy (i.e., statin resistance).⁹⁷

The AACE also published a “consensus statement” on the “comprehensive type 2 diabetes management algorithm.” The guideline includes a set of PowerPoint slides at the bottom, which recommend measuring Lp(a) in the following settings: presence of family history of premature ASCVD and/or increased Lp(a), and all patients with premature or recurrent ASCVD despite LDL-C lowering.⁹⁸

European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Guidelines for the Management of Dyslipidaemias

The ESC published 2021 guidelines on cardiovascular disease prevention in clinical practice. Their recommendations for CVD risk assessment are included below:⁹⁹

Recommendations for CVD Risk Assessment (Visseren, Mach, Smulders, Carballo, Koskinas, Back, et al., 2021)

Recommendations	Class ^a	Level ^b
Systematic global CVD risk assessment is recommended in individuals with any major vascular risk factor (i.e. family history of premature CVD, FH, CVD risk factors such as smoking, arterial hypertension, DM, raised lipid level, obesity, or comorbidities increasing CVD risk).	I	C
Systematic or opportunistic CV risk assessment in the general population in men >40 years of age and in women >50 years of age or postmenopausal with no known ASCVD risk factors may be considered. ⁹	IIb	C
In those individuals who have undergone CVD risk assessment in the context of opportunistic screening, a repetition of screening after 5 years (or sooner if risk was close to treatment thresholds) may be considered.	IIb	C
Opportunistic screening of BP in adults at risk for the development of hypertension, such as those who are overweight or with a known family history of hypertension, should be considered. ¹⁹	IIa	B
Systematic CVD risk assessment in men <40 years of age and women <50 years of age with no known CV risk factors is not recommended. ⁹	III	C

© ESC 2021

The authors include additional recommendations for CVD risk estimation and modification that are tabulated in the full guideline.

The 2019 guidelines from ESC and EAS provided the following recommendations:

- “Lp(a) measurement should be considered at least once in each adult person’s lifetime to identify those with very high inherited Lp(a) levels >180 mg/dL (>430 nmol/L) who may have a lifetime risk of ASCVD equivalent to the risk associated with heterozygous familial hypercholesterolemia.

Reimbursement Policy:

Cardiovascular Disease Risk Assessment - Lab Benefit Program (LBM)

- “Persons with documented ASCVD, type 1 or type 2 DM (T1DM and T2DM, respectively), very high levels of individual risk factors, or chronic kidney disease (CKD) are generally at very-high or high total CV risk. No risk estimation models are needed for such persons...”
- ApoB analysis is recommended for risk assessment, particularly in people with high TG, DM, obesity or metabolic syndrome, or very low LDL-C. It can be used as an alternative to LDL-C, if available, as the primary measurement for screening, diagnosis, and management, and may be preferred over non-HDL-C in people with high TG, DM, obesity, or very low LDL-C.
- CAC score assessment with CT may be helpful in reaching decisions about treatment in people who are at moderate risk of ASCVD. Obtaining such a score may assist in discussions about treatment strategies in patients where the LDL-C goal is not achieved with lifestyle intervention alone and there is a question of whether to institute LDL-C-lowering treatment. Assessment of arterial (carotid or femoral) plaque burden on ultrasonography may also be informative in these circumstances.”¹⁸

Total cholesterol may be used to estimate total cardiovascular risk. LDL-C is recommended to be used as the primary lipid analysis for diagnosis, management, screening, and risk estimation. HDL-C and non-HDL-C are also strong, independent risk factors.¹⁰⁰

Apolipoprotein B, Lp(a), Apo B/Apo A-I, and non-HDL-C/HDL-C may all be used as alternative markers for cardiovascular risk. The guidelines note that measuring Apo B and Apo A-I is convenient, accurate, does not require fasting, and is not susceptible to TG levels. The guidelines also recommend against routine measurement of Apo C-III as its use is unknown.¹⁰⁰

In the 2021 ESC Guidelines on cardiovascular disease prevention, the authors stated that “New studies confirm that C-reactive protein has limited additional value. There is renewed interest in lipoprotein(a), but it too provides limited additional value in terms of reclassification potential. Cardiac biomarkers are promising, but further work is needed.”⁹⁹

European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD)

This joint guideline was published for “diabetes, pre-diabetes, and cardiovascular diseases.” Their specific recommendations relating to cardiovascular risk assessment in patients with diabetes and pre-diabetes are as follows:

- “Routine assessment of microalbuminuria should be carried out to identify patients at risk of developing renal dysfunction and/or CVD.”
- “A resting electrocardiogram (ECG) is indicated in patients with DM and hypertension, or if CVD is suspected.”
- “Other tests, such as transthoracic echocardiography, coronary artery calcium (CAC) score, and ankle-brachial index (ABI), may be considered to test for structural heart disease or as risk modifiers in those at moderate or high risk of CVD.”
- “Routine assessment of novel biomarkers is not recommended for CV risk stratification.”

The guideline noted that “the addition of circulating biomarkers for CV risk assessment has limited clinical value” and stated that “in patients with DM without known CVD, measurement of C-reactive protein or fibrinogen (inflammatory markers) provides minor incremental value to current risk assessment.” Cosentino, et al. (2020) guideline also noted high-sensitivity cardiac troponin T as not adding incremental “discriminative power” for patients with DM without known CVD, although elevated high-sensitivity cardiac troponin T was noted as an independent predictor of renal decline and CV events in patients with type 1 diabetes.¹⁰¹

Reimbursement Policy:

Cardiovascular Disease Risk Assessment - Lab Benefit Program (LBM)

Endocrine Society (ES)

This guideline was published with the intent to assess and treat dyslipidemia in patients with endocrine disorders. Their relevant recommendations are listed below:

- “In adults with endocrine disorders, we recommend a lipid panel for the assessment of triglyceride levels and for calculating low-density lipoprotein cholesterol.”
- “In adults with endocrine disorders, we recommend conducting a cardiovascular risk assessment by evaluating traditional risk factors, including the calculation of 10-year atherosclerotic cardiovascular disease risk using a tool such as the Pooled Cohort Equations.”
- “In adults with endocrine disorders at borderline or intermediate risk (10-year atherosclerotic cardiovascular disease risk 5%–19.9%), particularly those with additional risk-enhancing factors, in whom the decision about statin treatment and/or other preventive interventions is uncertain, we suggest measuring coronary artery calcium to inform shared decision making.”

The guideline also remarks that certain “advanced” lipid testing (assessment of markers such as Apo B, lipid fractionation, and Lp(a)) may be helpful in “characterizing” lipid abnormalities, but “add little” to risk prediction beyond the standard lipid profile.

The guideline goes on to discuss Lp(a), noting that the marker can be helpful in assessing familial risk, but adds “little” in terms of global risk assessment across the general population. The guideline acknowledges other evidence supporting Lp(a)’s use as a marker to manage treatment. Other serum biomarkers and biomarker panels were also considered to add “little” to global risk assessment. Finally, the guideline recommends the use of hs-CRP as a “risk-enhancing factor that may drive more aggressive treatment or the need for advanced risk assessment.”¹⁰²

Rosenzweig, et al. (2019) published on the Primary Prevention of ASCVD and T2DM in Patients at Metabolic Risk. A summary of the recommendations is included below:¹⁰³

- “In individuals aged 40–75 years in the office setting, we suggest providers screen for all five components of metabolic risk at the clinical visit. The finding of at least three components should specifically alert the clinician to a patient at metabolic risk (at higher risk for atherosclerotic cardiovascular disease and type 2 diabetes mellitus).
- In individuals aged 40–75 years in the office setting who do not yet have atherosclerotic cardiovascular disease or type 2 diabetes mellitus and already have at least one risk factor, we advise screening every 3 years for all five components of metabolic risk as part of the routine clinical examination.
- To establish metabolic risk in the general population, we recommend that clinicians measure waist circumference as a routine part of the clinical examination.
- In individuals previously diagnosed with prediabetes, we suggest testing at least annually for the presence of overt type 2 diabetes mellitus.
- We recommend that all individuals at metabolic risk in the office setting have their blood pressure measured annually and, if elevated, at each subsequent visit.
- For individuals with elevated blood pressure above 130 mmHg systolic and/or 80 mmHg diastolic who are not documented as having a history of hypertension, we recommend confirmation of elevated blood pressure on a separate day within a few weeks or with a home blood pressure monitor.”

Reimbursement Policy:

Cardiovascular Disease Risk Assessment - Lab Benefit Program (LBM)

Components of “metabolic risk” are defined as:

- elevated blood pressure
- increased waist circumference
- elevated fasting triglycerides
- low high-density lipoprotein-cholesterol, and
- elevated glycemia

American Society for Clinical Pathology

The ASCP recommends against routinely ordering expanded lipid panels (such as particle sizing or nuclear magnetic resonance) as screening for cardiovascular disease.¹⁰⁴

In 2022, the ASCP published a set of clinical recommendations aiming to provide the guidance and the tools for assessment of ASCVD risk with the goal of appropriately targeting treatment approaches for prevention of ASCVD events, as shown below:

“1 Assessing a patient's risk for ASCVD is the foundation of preventive cardiology and the initial step for determining the appropriateness and intensity of preventive treatment.

2 In primary prevention, global risk scoring is the initial stage for ASCVD risk assessment, providing a calculation of ASCVD risk from a set of standard office-based risk factors for a specified duration (e.g., 10 years) of time, from which a clinician-patient risk discussion is used to discuss the best ways to reduce CVD risk.

3 The presence, quantity, and/or extent of one or more risk enhancing factors, including premature family history, persistently elevated LDL-C, or CKD, as well as severity of certain inflammatory factors such as hs-CRP and laboratory measures such as Lp(a), can further inform the treatment decision.

4 In women, it is important to take a comprehensive reproductive history from menarche to menopause, including preeclampsia, premature menopause, and autoimmune disease as “risk-enhancing” factors.

5 Race/ethnicity may have a significant impact on the validity of current risk assessment tools and certain higher risk race/ethnic groups may further inform the use of preventive therapy.

6 Social determinants of health may exert independent effects beyond race/ethnicity and need also to be part of the clinician-patient discussion when discussing the most appropriate ways to optimize ASCVD risk.

7 Among subclinical atherosclerotic disease screening tests, CAC is probably the most useful, providing substantial improvement of risk reclassification over global risk scoring in most primary prevention groups, including diabetes. In addition to the consideration of risk enhancing factors (discussed earlier), CAC testing can be used to further inform treatment decisions for preventive therapy, including statin and aspirin use in particular.

8 The use of ABI for assessment of PAD is also valuable and can improve risk reclassification beyond global risk scoring.

9 Carotid ultrasound imaging, if accompanied by carotid plaque assessment may also be useful for risk assessment, especially as an option when CAC scoring is not available.

Reimbursement Policy:

Cardiovascular Disease Risk Assessment - Lab Benefit Program (LBM)

10 In patients with pre-existing ASCVD, stratification into those at highest risk (e.g., very high risk ASCVD status) for more aggressive treatment is based on the history of multiple major ASCVD events or one major event and multiple high-risk conditions. Moreover, those with recurrent ASCVD events in the short-term define an extreme risk condition warranting even more aggressive risk factor management.”¹⁰⁵

National Institute for Health and Care Excellence (NICE)

A baseline lipid profile should be taken before treatment. This should include TC, HDL cholesterol, non-HDL, and triglyceride levels. Total and HDL cholesterol should be measured for best estimate of CVD risk.

Omega-3 compounds have “no evidence” to help prevent CVD and NICE recommends against distribution of these compounds for CVD treatment.¹⁰⁶

United States Preventive Services Task Force (USPSTF)

The USPSTF Task Force Recommendations include periodic assessment of cardiovascular risk factors from ages 40 to 75 years, including measurement of TC, LDL-C, and HDL-C levels. The optimal intervals for cardiovascular risk assessment are uncertain. Based on other guidelines and expert opinion, reasonable options include annual assessment of blood pressure and smoking status and measurement of lipid levels every five years. Shorter intervals may be useful for persons at higher risk, and longer intervals are appropriate for persons who are regularly at average risk.¹⁰⁷

The USPSTF found insufficient evidence that screening for dyslipidemia in younger adults influences cardiovascular outcomes, and no studies that evaluated the effects of screening vs no screening, treatment vs no treatment, or delayed vs earlier treatment in adults in this age group. Thus, the USPSTF recommends neither for nor against screening for dyslipidemia in this age group. The USPSTF also noted there was insufficient evidence to assess the balance of benefits and harms of screening for dyslipidemia in children and adolescents.¹⁰⁸

The USPSTF states that “current evidence is insufficient to assess the benefits and harms of adding ankle-brachial index (ABI), high-sensitivity C-reactive protein (hsCRP) level, or coronary artery calcium (CAC) score to traditional risk assessment for cardiovascular disease (CVD) in asymptomatic adults to prevent CVD events.”¹⁰⁹ However, the USPSTF recommends screening for abnormal blood glucose for adults aged 40-70 who are overweight or obese.¹¹⁰

For adults at low risk of CVD events, “The USPSTF recommends against screening with resting or exercise electrocardiography (ECG) to prevent cardiovascular disease (CVD) events” (recommendation grade D, discouraging the use of the service). Moreover, “The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening with resting or exercise ECG to prevent CVD events in asymptomatic adults at intermediate or high risk of CVD events” (recommendation grade I, insufficient evidence).¹¹¹

The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for primary hypertension in asymptomatic children and adolescents to prevent subsequent cardiovascular disease.¹¹² A 2020 recommendation statement by the USPSTF confirmed that the current evidence is insufficient to assess the balance of benefits and harms of screening for high blood pressure in children and adolescents (in general).¹¹³ In adults, however, USPSTF recommends screening for hypertension (persons 18 years or older) with office blood pressure measurement. The USPSTF recommends obtaining blood pressure measurements outside of the clinical setting for diagnostic confirmation before starting treatment.¹¹⁴

Finally, screening for obesity in children six years or older is recommended.¹⁰⁷

Reimbursement Policy:

Cardiovascular Disease Risk Assessment - Lab Benefit Program (LBM)

Canadian Cardiovascular Society (CCS)

In 2021, the CCS published updated their recommendations on the management of dyslipidemia for the prevention of cardiovascular disease in adults. A summary of the society's recommendations that are relevant to CVD risk assessment is provided below:

- “Among women whose pregnancy was complicated by the hypertensive disorders of pregnancy -- gestational hypertension and/or preeclampsia -- or a preterm birth before 34 weeks’ gestation, a stillbirth and/or a placental abruption, we recommend screening with a comprehensive lipid panel at least 12 weeks postpartum. These women have a higher risk of premature CVD and stroke within 10-15 years after the affected pregnancy (Strong Recommendation, Moderate Quality Evidence).
- To assist with decisions about initiating lipid-lowering pharmacotherapy in a nonpregnant woman who had one or more of these pregnancy complications, we recommend referral to a specialized postpartum cardiovascular health clinic or specialized lipid clinic, if locally available. If such resources are not locally available, we recommend using standard risk assessment tools to decide about lipid-lowering pharmacotherapy. However, when interpreting their 10-year CVD risk using a risk calculator, it is important to note that most women in this group will be found to have a low calculated absolute risk of CVD, short-term, which may give a false sense of reassurance to both the patient and her health care provider. (Weak Recommendation; Low-Quality Evidence).
- For any patient with triglycerides > 1.5mM, use non-HDL-C or apoB instead of LDL-C as the preferred lipid parameter for initial screening and treatment target (< 2.6 mM for non-HDL-C or < 0.8 g/L for apoB) in intermediate or high risk individuals (Strong Recommendation, High-Quality Evidence).
- We recommend measuring lipoprotein (a) level once in a person’s lifetime as a part of the initial lipid screening (Strong Recommendation; High-Quality Evidence).
- We suggest that CAC [coronary artery calcium] screening using computed tomography imaging might be considered for asymptomatic adults 40 years or older and at intermediate risk (FRS 10%-20%) for whom treatment decisions are uncertain (Strong Recommendation, Moderate-Quality Evidence).
- We recommend that CAC screening using computed tomography imaging not be undertaken for: (1) high-risk individuals; (2) patients receiving statin treatment; or (3) most asymptomatic, low-risk adults (Strong Recommendation; Moderate-Quality Evidence).
- We suggest that CAC screening might be considered for a subset of low-risk individuals 40 years or older (Weak Recommendation; Low-Quality Evidence).¹¹⁵

The 2021 guidelines affirmed those from 2016, stating that “Screening should be repeated every 5 years for men and women aged 40-75 years using the modified FRS or Cardiovascular Life Expectancy Model (CLEM) to guide therapy to reduce major CV events.”

A revision of the 2016 recommendation is the role of Lp(a): “Lp(a) is not currently considered a treatment target and repeat measures are therefore not indicated.” Moreover, non-fasting lipid testing is recommended during the CV risk assessment, and “It is now generally preferable to follow non-HDL-C or ApoB levels over LDL-C when interpreting lipid results, particularly when TG are ≥ 1.5 mmol/L.”¹¹⁵

Reimbursement Policy:

Cardiovascular Disease Risk Assessment - Lab Benefit Program (LBM)

HIV Medicine Association of the Infectious Diseases Society of America

HIV-infected patients commonly develop dyslipidemia after starting antiretroviral therapy (ART). The lipid abnormalities developed in HIV-infected patients are associated with increased cardiovascular risk. HIV Medicine Association of the Infectious Diseases Society of America have updated their guidelines in 2013 to include a new section on metabolic comorbidities. They recommend obtaining a fasting lipid profile prior to and within 1-3 months after starting ART and every 6-12 months in all patients. The 2020 update affirms this, as under the workup for routine healthcare maintenance considerations for persons with HIV, they recommend the following steps: “Lipid profile: perform every 5 years if normal; more frequently if abnormal or other cardiovascular risk factors present (every 6–12 months); if abnormal, repeat fasting” and ask that clinicians “Follow the atherosclerotic cardiovascular disease risk calculator. Consider testing 1–3 months after starting or changing ART.”¹¹⁶

The Association also notes that HbA1c may be tested or used for screening and states that a lower cutoff of 5.8% for diabetes may be used for patients on ART instead of the higher 6.5%. Finally, the Association recommends measuring HbA1c every six months in patients with diabetes.^{116,117}

According to the Association, an initial evaluation and an immediate follow-up for persons with HIV includes “A comprehensive present and past medical history that includes HIV-related information, medication/social/family history..., review of systems, and physical examination... should be obtained for all patients upon initiation of care, ideally at the first visit or, if not feasible, as soon as possible thereafter,” and this includes testing for “Cardiovascular disease and risk factors, including hyperlipidemia, hypertension, diabetes mellitus, smoking.”¹¹⁶

U.S. Department of Veterans Affairs (VA) and U.S. Department of Defense (DoD)

The United States VA and DoD published a joint guideline regarding management of dyslipidemia for reducing CVD risk in adults. Their relevant recommendations are listed below:

- “For primary prevention in patients over age 40 and not on statin therapy who have not developed new cardiovascular risk factors (e.g., diabetes, hypertension, tobacco use), we suggest against offering a cardiovascular disease risk assessment more frequently than every five years.”
- “For primary prevention in patients not on statin therapy, we suggest against routinely ordering a lipid panel more frequently than every 10 years.”
- “For cardiovascular risk assessment in primary prevention, we suggest using a 10-year risk calculator.”
- “We suggest against the routine use of coronary artery calcium testing.”
- “We suggest against the routine use of additional risk markers (e.g., high-sensitivity C-reactive protein, ankle-brachial index, coronary artery calcium) when assessing cardiovascular risk.”

The guideline also remarks that several other markers, such as “coronary artery calcium (CAC), high-sensitivity C-reactive protein, ankle-brachial index, and apolipoprotein evaluations” have been proposed as useful tools to determine risk. However, these markers have been deemed “limited in further refining risk.” Although CAC was considered to best of the markers listed, the guideline still recommended against routine CAC testing.

The guideline also recommends against “routine lipid level testing for risk assessment and monitoring, unless it is specifically intended to guide decision making.”¹¹⁸

Reimbursement Policy:

Cardiovascular Disease Risk Assessment - Lab Benefit Program (LBM)

2021 European Society of Cardiology (ESC) and Other Societies on Cardiovascular Disease Prevention in Clinical Practice

In 2021, the Seventh Joint Task Force of the ESC and Other Societies on Cardiovascular Disease Prevention in Clinical Practice published guidelines on cardiovascular disease prevention in clinical practice.

The 2021 update has the same goals and targets for LDL-C, BP, and glycemic control in patients with DM as the previous 2016 guideline.

The authors state that routine assessment of circulating or urinary biomarkers is still not recommended for CVD risk stratification. The Task Force states that there is conflicting data on the utility of these biomarkers (such as hs-CRP, various apolipoproteins, etc.) and that new studies confirm that CRP has “limited additional value.” The authors concede that there is renewed interest in lipoprotein a, but that it doesn’t add additional value in risk stratification. While cardiac biomarkers show promise, additional clinical studies are necessary.

The Task Force recommends repeating risk assessment every five years, and more often for higher risk patients. However, the Task Force only recommends this screening procedure for men >40 years and women >50 years, declaring that, though it is not cost-effective, a systematic CVD risk assessment is shown to “increase detection of CV risk factors.”⁹⁹

Applicable State and Federal Regulations:

DISCLAIMER: If there is a conflict between this Policy and any relevant, applicable government policy for a particular member [e.g., Local Coverage Determinations (LCDs) or National Coverage Determinations (NCDs) for Medicare and/or state coverage for Medicaid], then the government policy will be used to make the determination. For the most up-to-date Medicare policies and coverage, please visit the Medicare search website: <https://www.cms.gov/medicare-coverage-database/search.aspx>. For the most up-to-date Medicaid policies and coverage, visit the applicable state Medicaid website.

Food and Drug Administration (FDA)

Many labs have developed specific tests that they must validate and perform in house. These laboratory-developed tests (LDTs) are regulated by the Centers for Medicare and Medicaid (CMS) as high-complexity tests under the Clinical Laboratory Improvement Amendments of 1988 (CLIA '88). LDTs are not approved or cleared by the U. S. Food and Drug Administration; however, FDA clearance or approval is not currently required for clinical use.

Applicable CPT/HCPCS Procedure Codes:

CPT	Code Description
80061	Lipid panel This panel must include the following: Cholesterol, serum, total (82465) Lipoprotein, direct measurement, high density cholesterol (HDL cholesterol) (83718) Triglycerides (84478)
81599	Unlisted multianalyte assay with algorithmic analysis
82172	Apolipoprotein, each

Reimbursement Policy:

Cardiovascular Disease Risk Assessment - Lab Benefit Program (LBM)

CPT	Code Description
82465	Cholesterol, serum or whole blood, total
82610	Cystatin C
83090	Homocysteine
83695	Lipoprotein (a)
83698	Lipoprotein-associated phospholipase A2 (Lp-PLA2)
83700	Lipoprotein, blood; electrophoretic separation and quantitation
83701	Lipoprotein, blood; high resolution fractionation and quantitation of lipoproteins including lipoprotein subclasses when performed (eg, electrophoresis, ultracentrifugation)
83704	Lipoprotein, blood; quantitation of lipoprotein particle number(s) (eg, by nuclear magnetic resonance spectroscopy), includes lipoprotein particle subclass(es), when performed
83718	Lipoprotein, direct measurement; high density cholesterol (HDL cholesterol)
83719	Lipoprotein, direct measurement; VLDL cholesterol
83721	Lipoprotein, direct measurement; LDL cholesterol
83722	Lipoprotein, direct measurement; small dense LDL cholesterol
83880	Natriuretic peptide
84478	Triglycerides
84484	Troponin, quantitative
84512	Troponin, qualitative
84999	Unlisted chemistry procedure
85384	Fibrinogen; activity
85415	Fibrinolytic factors and inhibitors; plasminogen activator
86140	C-reactive protein
86141	C-reactive protein; high sensitivity (hsCRP)

Current Procedural Terminology© American Medical Association. All Rights reserved.

Procedure codes appearing in Medical Policy documents are included only as a general reference tool for each policy. They may not be all-inclusive.

Evidence-based Scientific References:

1. Goff DC, Jr., Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Journal of the American College of Cardiology*. Jul 1 2014;63(25 Pt B):2935-59. doi:10.1016/j.jacc.2013.11.005
2. AHA. 2025 Heart Disease and Stroke Statistics Update Fact Sheet. <https://www.heart.org/en/-/media/PHD-Files-2/Science-News/2/2025-Heart-and-Stroke-Stat-Update/2025-Statistics-At-A-Glance.pdf>
3. Wilson P. Overview of the possible risk factors for cardiovascular disease. Updated November 21, 2024. <https://www.uptodate.com/contents/overview-of-possible-risk-factors-for-cardiovascular-disease>

Reimbursement Policy:

Cardiovascular Disease Risk Assessment - Lab Benefit Program (LBM)

4. Rosenson R. Measurement of blood lipids and lipoproteins. Updated October 1, 2024. <https://www.uptodate.com/contents/measurement-of-blood-lipids-and-lipoproteins>
5. MacNamara J, Eapen DJ, Quyyumi A, Sperling L. Novel biomarkers for cardiovascular risk assessment: current status and future directions. *Future cardiology*. Sep 2015;11(5):597-613. doi:10.2217/fca.15.39
6. Wilson P. Atherosclerotic cardiovascular disease risk assessment for primary prevention in adults. Updated September 20, 2024. <https://www.uptodate.com/contents/atherosclerotic-cardiovascular-disease-risk-assessment-for-primary-prevention-in-adults-our-approach>
7. Rosenson R, Stein J, Durrington P. Lipoprotein(a). Updated April 15, 2025. <https://www.uptodate.com/contents/lipoprotein-a-and-cardiovascular-disease>
8. Rosenson R. Lipoprotein classification, metabolism, and role in atherosclerosis. Updated October 23, 2023. <https://www.uptodate.com/contents/lipoprotein-classification-metabolism-and-role-in-atherosclerosis>
9. Antonopoulos AS, Angelopoulos A, Papanikolaou P, et al. Biomarkers of Vascular Inflammation for Cardiovascular Risk Prognostication: A Meta-Analysis. *JACC Cardiovasc Imaging*. Mar 2022;15(3):460-471. doi:10.1016/j.jcmg.2021.09.014
10. Chiesa ST, Charakida M, Georgiopoulos G, et al. Glycoprotein Acetyls: A Novel Inflammatory Biomarker of Early Cardiovascular Risk in the Young. *J Am Heart Assoc*. Feb 15 2022;11(4):e024380. doi:10.1161/jaha.121.024380
11. Morita SY. Metabolism and Modification of Apolipoprotein B-Containing Lipoproteins Involved in Dyslipidemia and Atherosclerosis. *Biol Pharm Bull*. 2016;39(1):1-24. doi:10.1248/bpb.b15-00716
12. Trompet S, Packard CJ, Jukema JW. Plasma apolipoprotein-B is an important risk factor for cardiovascular disease, and its assessment should be routine clinical practice. *Curr Opin Lipidol*. Feb 2018;29(1):51-52. doi:10.1097/mol.0000000000000476
13. Robinson JG, Williams KJ, Gidding S, et al. Eradicating the Burden of Atherosclerotic Cardiovascular Disease by Lowering Apolipoprotein B Lipoproteins Earlier in Life. *J Am Heart Assoc*. Oct 16 2018;7(20):e009778. doi:10.1161/jaha.118.009778
14. Tedeschi-Reiner E, Strozzi M, Skoric B, Reiner Z. Relation of atherosclerotic changes in retinal arteries to the extent of coronary artery disease. *Am J Cardiol*. Oct 15 2005;96(8):1107-9. doi:10.1016/j.amjcard.2005.05.070
15. Lamprea-Montealegre JA, Staplin N, Herrington WG, et al. Apolipoprotein B, Triglyceride-Rich Lipoproteins, and Risk of Cardiovascular Events in Persons with CKD. *Clin J Am Soc Nephrol*. Jan 7 2020;15(1):47-60. doi:10.2215/cjn.07320619
16. Cao J, Nomura SO, Steffen BT, et al. Apolipoprotein B discordance with low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol in relation to coronary artery calcification in the Multi-Ethnic Study of Atherosclerosis (MESA). *J Clin Lipidol*. Nov 29 2019;doi:10.1016/j.jacl.2019.11.005
17. Hwang YC, Ahn HY, Han KH, Park SW, Park CY. Prediction of future cardiovascular disease with an equation to estimate apolipoprotein B in patients with high cardiovascular risk: an analysis from the TNT and IDEAL study. *Lipids Health Dis*. Aug 22 2017;16(1):158. doi:10.1186/s12944-017-0549-8
18. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. *Eur Heart J*. Aug 31 2019;doi:10.1093/eurheartj/ehz455
19. Sandhu PK, Musaad SM, Remaley AT, et al. Lipoprotein Biomarkers and Risk of Cardiovascular Disease: A Laboratory Medicine Best Practices (LMBP) Systematic Review. *The journal of applied laboratory medicine*. Sep 1 2016;1(2):214-229. doi:10.1373/jalm.2016.021006
20. Kuwahara K, Nakagawa Y, Nishikimi T. Cutting Edge of Brain Natriuretic Peptide (BNP) Research - The Diversity of BNP Immunoreactivity and Its Clinical Relevance. *Circ J*. Sep 25 2018;82(10):2455-2461. doi:10.1253/circj.CJ-18-0824
21. Li N, Wang JA. Brain natriuretic peptide and optimal management of heart failure. *J Zhejiang Univ Sci B*. Sep 2005;6(9):877-84.
22. Tomcsányi J, Somló M, Bózsik B, Frész T, Nagy E. [The value of early repeated N-terminal pro-B-type natriuretic peptide measurement in acute heart failure]. *Orv Hetil*. Jun 2018;159(25):1009-1012. Az N-terminális pro-B natriureticus peptid mérésének korai ismétlése akut szívelégtelenség miatt hospitalizált betegekben. doi:10.1556/650.2018.31095

Reimbursement Policy:

Cardiovascular Disease Risk Assessment - Lab Benefit Program (LBM)

23. Mark DB, Cowper PA, Anstrom KJ, et al. Economic and Quality-of-Life Outcomes of Natriuretic Peptide-Guided Therapy for Heart Failure. *Journal of the American College of Cardiology*. Nov 27 2018;72(21):2551-2562. doi:10.1016/j.jacc.2018.08.2184
24. Colucci W, Chen HH. Natriuretic peptide measurement in heart failure. Updated March 11, 2024. <https://www.uptodate.com/contents/natriuretic-peptide-measurement-in-heart-failure>
25. Januzzi JL, Jr., Ahmad T, Mulder H, et al. Natriuretic Peptide Response and Outcomes in Chronic Heart Failure With Reduced Ejection Fraction. *Journal of the American College of Cardiology*. Sep 3 2019;74(9):1205-1217. doi:10.1016/j.jacc.2019.06.055
26. Rosenson R, Durrington P. HDL cholesterol: Clinical aspects of abnormal values. Updated August 6, 2024. <https://www.uptodate.com/contents/hdl-cholesterol-clinical-aspects-of-abnormal-values>
27. Grundy SM, Stone Neil J, Bailey Alison L, et al. 2018
AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*. 2019/06/18 2018;139(25):e1082-e1143. doi:10.1161/CIR.0000000000000625
28. Willeit P, Ridker PM, Nestel PJ, et al. Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. *Lancet (London, England)*. Oct 13 2018;392(10155):1311-1320. doi:10.1016/s0140-6736(18)31652-0
29. Mehta A, Virani SS, Ayers CR, et al. Lipoprotein(a) and Family History Predict Cardiovascular Disease Risk. *Journal of the American College of Cardiology*. Aug 18 2020;76(7):781-793. doi:10.1016/j.jacc.2020.06.040
30. Rule A, Glasscock, Richard. The aging kidney. Updated September 3, 2024. <https://www.uptodate.com/contents/the-aging-kidney>
31. Sarnak M, Gibson, Michael, Henrich, William. Chronic kidney disease and coronary heart disease. Updated May 16, 2023. <https://www.uptodate.com/contents/chronic-kidney-disease-and-coronary-heart-disease>
32. Maners J, Gill D, Pankratz N, Tang W. Abstract P106: Genetically Determined Fibrinogen, Gamma Prime Fibrinogen and Risk of Venous Thromboembolism and Ischemic Stroke: Evidence From Mendelian Randomization. *American Heart Association*. 2019;doi:10.1161/circ.139.suppl_1.P106
33. Pieters M, Ferreira M, de Maat MPM, Ricci C. Biomarker association with cardiovascular disease and mortality - The role of fibrinogen. A report from the NHANES study. *Thromb Res*. Dec 16 2020;198:182-189. doi:10.1016/j.thromres.2020.12.009
34. Yang H, Guo W, Li J, et al. Leptin concentration and risk of coronary heart disease and stroke: A systematic review and meta-analysis. *PloS one*. 2017;12(3):e0166360. doi:10.1371/journal.pone.0166360
35. Liu G, Dong M, Ma S, et al. Serum leptin is associated with first-ever ischemic stroke, lesion size and stroke severity in a Chinese cohort. *Neurol Res*. Feb 2019;41(2):125-131. doi:10.1080/01616412.2018.1544399
36. Pignone MP. Low-density lipoprotein cholesterol-lowering therapy in the primary prevention of cardiovascular disease. Updated June 27, 2024. <https://www.uptodate.com/contents/management-of-elevated-low-density-lipoprotein-cholesterol-ldl-c-in-primary-prevention-of-cardiovascular-disease>
37. Reklou A, Katsiki N, Karagiannis A, Athyros V. Effects of Lipid Lowering Drugs on Arterial Stiffness: One More Way to Reduce Cardiovascular Risk? *Curr Vasc Pharmacol*. 2020;18(1):38-42. doi:10.2174/1570161117666190121102323
38. Kongpakwattana K, Ademi Z, Chaiyasothi T, et al. Cost-Effectiveness Analysis of Non-Statin Lipid-Modifying Agents for Secondary Cardiovascular Disease Prevention Among Statin-Treated Patients in Thailand. *Pharmacoeconomics*. Oct 2019;37(10):1277-1286. doi:10.1007/s40273-019-00820-6
39. Boekholdt SM, Hovingh GK, Mora S, et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. *Journal of the American College of Cardiology*. Aug 5 2014;64(5):485-94. doi:10.1016/j.jacc.2014.02.615
40. Beauchemin M, Geguchadze R, Guntur AR, et al. Exploring mechanisms of increased cardiovascular disease risk with antipsychotic medications: Risperidone alters the cardiac proteomic signature in mice. *Pharmacol Res*. Dec 23 2019;152:104589. doi:10.1016/j.phrs.2019.104589

Reimbursement Policy:

Cardiovascular Disease Risk Assessment - Lab Benefit Program (LBM)

41. Polcwiartek C, Kragholm K, Schjerning O, Graff C, Nielsen J. Cardiovascular safety of antipsychotics: a clinical overview. *Expert Opin Drug Saf.* May 2016;15(5):679-88. doi:10.1517/14740338.2016.1161021
42. Howell S, Yarovova E, Khwanda A, Rosen SD. Cardiovascular effects of psychotic illnesses and antipsychotic therapy. *Heart.* Dec 2019;105(24):1852-1859. doi:10.1136/heartjnl-2017-312107
43. Kilicaslan EE, Karakilic M, Erol A. The Relationship between 10 Years Risk of Cardiovascular Disease and Schizophrenia Symptoms: Preliminary Results. *Psychiatry Investig.* Dec 2019;16(12):933-939. doi:10.30773/pi.2019.0063
44. Rotella F, Cassioli E, Calderani E, et al. Long-term metabolic and cardiovascular effects of antipsychotic drugs. A meta-analysis of randomized controlled trials. *Eur Neuropsychopharmacol.* Jan 6 2020;doi:10.1016/j.euroneuro.2019.12.118
45. Pile HD, Sadiq NM. Isotretinoin. *StatPearls.* StatPearls Publishing; 2019.
46. Güler E, Babur Güler G, Yavuz C, Kızıllırmak F. An unknown side effect of isotretinoin: pericardial effusion with atrial tachycardia. *Anatol J Cardiol.* Feb 2015;15(2):168-9.
47. Akcay M, Yuksel S. Isotretinoin-associated possible Kounis syndrome: A case report and a review of other cardiovascular side effects reported in the literature. *Türk Kardiyol Dern Ars.* Jun 2019;47(4):324-328. Isotretinoin ile ilişkili olası Kounis sendromu: Olgu sunumu ve diğer kardiyovasküler yan etkilerin literatür derlemesi. doi:10.5543/tkda.2018.67055
48. Alan S, Unal B, Yildirim A. Premature ventricular contractions associated with isotretinoin use. *An Bras Dermatol.* Nov-Dec 2016;91(6):820-821. doi:10.1590/abd1806-4841.20165138
49. Karadag AS, Gumrukcuoglu HA, Gunes Bilgili S, et al. Does isotretinoin therapy have any effects on electrocardiography, heart rate and blood pressure? *J Dermatolog Treat.* Jun 2012;23(3):168-71. doi:10.3109/09546634.2010.546831
50. Zane LT, Leyden WA, Marqueling AL, Manos MM. A population-based analysis of laboratory abnormalities during isotretinoin therapy for acne vulgaris. *Arch Dermatol.* Aug 2006;142(8):1016-22. doi:10.1001/archderm.142.8.1016
51. Lee YH, Scharnitz TP, Muscat J, Chen A, Gupta-Elera G, Kirby JS. Laboratory Monitoring During Isotretinoin Therapy for Acne: A Systematic Review and Meta-analysis. *JAMA Dermatol.* Jan 2016;152(1):35-44. doi:10.1001/jamadermatol.2015.3091
52. Crea F, Morrow, David. C-reactive protein in cardiovascular disease. Updated November 18, 2024. <https://www.uptodate.com/contents/c-reactive-protein-in-cardiovascular-disease>
53. Mehta A, Blumenthal RS, Gluckman TJ, Feldman DI, Kohli P. High-sensitivity C-reactive Protein in Atherosclerotic Cardiovascular Disease: To Measure or Not to Measure? *US Cardiol.* 2025;19:e06. doi:10.15420/usc.2024.25
54. Rosenson RS, Smith CC, Bauer KA. Overview of homocysteine. Updated January 24, 2025. <https://www.uptodate.com/contents/overview-of-homocysteine>
55. Varbo A, Benn M, Tybjaerg-Hansen A, Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG. Remnant cholesterol as a causal risk factor for ischemic heart disease. *Journal of the American College of Cardiology.* Jan 29 2013;61(4):427-36. doi:10.1016/j.jacc.2012.08.1026
56. Jepsen A-MK, Langsted A, Varbo A, Bang LE, Kamstrup PR, Nordestgaard BG. Increased Remnant Cholesterol Explains Part of Residual Risk of All-Cause Mortality in 5414 Patients with Ischemic Heart Disease. *Clinical Chemistry.* 2016;62(4):593. doi:10.1373/clinchem.2015.253757
57. Joshi PH, Khokhar AA, Massaro JM, et al. Remnant Lipoprotein Cholesterol and Incident Coronary Heart Disease: The Jackson Heart and Framingham Offspring Cohort Studies. 2016-05-01 2016;doi:10.1161/JAHA.115.002765
58. Varbo A, Benn M, Nordestgaard BG. Remnant cholesterol as a cause of ischemic heart disease: evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment. *Pharmacology & therapeutics.* Mar 2014;141(3):358-67. doi:10.1016/j.pharmthera.2013.11.008
59. Di Angelantonio E, Sarwar N, Perry P, et al. Major lipids, apolipoproteins, and risk of vascular disease. *Jama.* Nov 11 2009;302(18):1993-2000. doi:10.1001/jama.2009.1619

Reimbursement Policy:

Cardiovascular Disease Risk Assessment - Lab Benefit Program (LBM)

60. Rosenson RS, Stafforini DM. Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2. *Journal of lipid research*. Sep 2012;53(9):1767-82. doi:10.1194/jlr.R024190
61. LPSC. Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. *The Lancet*. 2010/05/01 2010;375(9725):1536-1544. doi:10.1016/S0140-6736(10)60319-4
62. Garg PK, McClelland RL, Jenny NS, et al. Lipoprotein-associated phospholipase A2 and risk of incident cardiovascular disease in a multi-ethnic cohort: The multi ethnic study of atherosclerosis. *Atherosclerosis*. Jul 2015;241(1):176-82. doi:10.1016/j.atherosclerosis.2015.05.006
63. Sudhir K. Lipoprotein-associated phospholipase A2, vascular inflammation and cardiovascular risk prediction. *Vascular health and risk management*. 2006;2(2):153-6.
64. Mohler ER, 3rd, Ballantyne CM, Davidson MH, et al. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study. *Journal of the American College of Cardiology*. Apr 29 2008;51(17):1632-41. doi:10.1016/j.jacc.2007.11.079
65. De Stefano A, Mannucci L, Tamburi F, et al. Lp-PLA2, a new biomarker of vascular disorders in metabolic diseases. *Int J Immunopathol Pharmacol*. Jan-Dec 2019;33:2058738419827154. doi:10.1177/2058738419827154
66. Mozaffarian D. Fish oil: Physiologic effects and administration. Updated August 14, 2024. <https://www.uptodate.com/contents/fish-oil-physiologic-effects-and-administration>
67. de Oliveira Otto MC, Wu JH, Baylin A, et al. Circulating and dietary omega-3 and omega-6 polyunsaturated fatty acids and incidence of CVD in the Multi-Ethnic Study of Atherosclerosis. *J Am Heart Assoc*. Dec 18 2013;2(6):e000506. doi:10.1161/jaha.113.000506
68. Superko HR, Superko AR, Lundberg GP, et al. Omega-3 Fatty Acid Blood Levels Clinical Significance Update. *Curr Cardiovasc Risk Rep*. 2014;8(11)doi:10.1007/s12170-014-0407-4
69. Itakura H, Yokoyama M, Matsuzaki M, et al. Relationships between plasma fatty acid composition and coronary artery disease. *J Atheroscler Thromb*. 2011;18(2):99-107. doi:10.5551/jat.5876
70. Bosch J, Gerstein HC, Dagenais GR, et al. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. *The New England journal of medicine*. Jul 26 2012;367(4):309-18. doi:10.1056/NEJMoa1203859
71. Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. *Jama*. Sep 12 2012;308(10):1024-33. doi:10.1001/2012.jama.11374
72. Siscovick DS, Barringer TA, Fretts AM, et al. Omega-3 Polyunsaturated Fatty Acid (Fish Oil) Supplementation and the Prevention of Clinical Cardiovascular Disease: A Science Advisory From the American Heart Association. *Circulation*. Apr 11 2017;135(15):e867-e884. doi:10.1161/cir.0000000000000482
73. Gibson M, Morrow, D. Elevated cardiac troponin concentration in the absence of an acute coronary syndrome. Updated April 17, 2024. <https://www.uptodate.com/contents/elevated-cardiac-troponin-concentration-in-the-absence-of-an-acute-coronary-syndrome>
74. Jaffe A. Troponin testing: Analytical considerations. Updated April 17, 2024. <https://www.uptodate.com/contents/troponin-testing-analytical-considerations>
75. Ford I, Shah AS, Zhang R, et al. High-Sensitivity Cardiac Troponin, Statin Therapy, and Risk of Coronary Heart Disease. *Journal of the American College of Cardiology*. Dec 27 2016;68(25):2719-2728. doi:10.1016/j.jacc.2016.10.020
76. Tang O, Matsushita K, Coresh J, et al. High-Sensitivity Cardiac Troponin I for Risk Stratification in Older Adults. *J Am Geriatr Soc*. Nov 4 2020;doi:10.1111/jgs.16912
77. Suthahar N, Meems LMG, van Veldhuisen DJ, et al. High-Sensitivity Troponin-T and Cardiovascular Outcomes in the Community: Differences Between Women and Men. *Mayo Clin Proc*. Jun 2020;95(6):1158-1168. doi:10.1016/j.mayocp.2020.01.017

Reimbursement Policy:

Cardiovascular Disease Risk Assessment - Lab Benefit Program (LBM)

78. Genova Diagnostics. Cardio Check. <https://www.gdx.net/core/sample-reports/Cardio-Check-Sample-Report.pdf>
79. Cleveland HeartLab. The Science. <https://www.clevelandheartlab.com/providers/the-science/>
80. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*. Sep 10 2019;140(11):e596-e646. doi:10.1161/cir.0000000000000678
81. Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Journal of the American College of Cardiology*. Dec 14 2010;56(25):e50-103. doi:10.1016/j.jacc.2010.09.001
82. ACC. 2018 Guideline on the Management of Blood Cholesterol. Updated June 2019. <https://www.acc.org/-/media/Non-Clinical/Files-PDFs-Excel-MS-Word-etc/Guidelines/2018/Guidelines-Made-Simple-Tool-2018-Cholesterol.pdf>
83. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Hypertension (Dallas, Tex : 1979)*. Jun 2018;71(6):1269-1324. doi:10.1161/hyp.000000000000066
84. American Diabetes Association Professional Practice C. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2025. *Diabetes Care*. Jan 1 2025;48(Supplement_1):S207-S238. doi:10.2337/dc25-S010
85. ElSayed NA, Aleppo G, Aroda VR, et al. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2023. *Diabetes Care*. Jan 1 2023;46(Suppl 1):S158-S190. doi:10.2337/dc23-S010
86. American Diabetes A. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2021. *Diabetes Care*. Jan 2021;44(Suppl 1):S125-S150. doi:10.2337/dc21-S010
87. American Diabetes Association Professional Practice C. 14. Children and Adolescents: Standards of Care in Diabetes-2024. *Diabetes Care*. Jan 1 2024;47(Suppl 1):S258-S281. doi:10.2337/dc24-S014
88. Wilson DP, Jacobson TA, Jones PH, et al. Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. *J Clin Lipidol*. May-Jun 2019;13(3):374-392. doi:10.1016/j.jacl.2019.04.010
89. Wilson PWF, Jacobson TA, Martin SS, et al. Lipid measurements in the management of cardiovascular diseases: Practical recommendations a scientific statement from the national lipid association writing group. *Journal of Clinical Lipidology*. 2021;15(5):629-648. doi:10.1016/j.jacl.2021.09.046
90. CDC. Cardiovascular Disease Biomarker Standardization Programs. Updated April 24, 2024. <https://www.cdc.gov/clinical-standardization-programs/php/cvd/>
91. CDC. Heart Disease Risk Factors. Updated December 2, 2024. <https://www.cdc.gov/heart-disease/risk-factors/>
92. CDC. LSP: Lipids Standardization Program. Updated December, 2023. <https://wwwn.cdc.gov/dlsdata/lspds/pdf/UserManual.pdf>
93. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. *Circulation*. Jan 28 2003;107(3):499-511. doi:10.1161/01.cir.0000052939.59093.45
94. CMS. Lipid Testing <https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?NCDId=102>
95. Reyes-Soffer G, Ginsberg HN, Berglund L, et al. Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association. *Arterioscler Thromb Vasc Biol*. Jan 2022;42(1):e48-e60. doi:10.1161/ATV.0000000000000147
96. Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of

Reimbursement Policy:

Cardiovascular Disease Risk Assessment - Lab Benefit Program (LBM)

Cardiovascular Disease. *Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists*. Apr 2017;23(Suppl 2):1-87.

doi:10.4158/ep171764.appgl

97. AACE. Consensus Statement by The American Association Of Clinical Endocrinologists And American College Of Endocrinology On The Management Of Dyslipidemia And Prevention Of Cardiovascular Disease Algorithm – 2020 Executive Summary. 2021;
98. Garber AJ, Handelsman Y, Grunberger G, et al. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm– 2020 Executive Summary. *Endocrine Practice*. 2020/01/01 2020;26(1):107-139. doi:10.4158/CS-2019-0472
99. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC). *European Heart Journal*. 2021;42(34):3227-3337. doi:10.1093/eurheartj/ehab484
100. Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. *Eur Heart J*. Oct 14 2016;37(39):2999-3058. doi:10.1093/eurheartj/ehw272
101. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). *European Heart Journal*. 2020;41(2):255-323. doi:10.1093/eurheartj/ehz486
102. Newman CB, Blaha MJ, Boord JB, et al. Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline. *The Journal of Clinical Endocrinology & Metabolism*. 2020;105(12):3613-3682. doi:10.1210/clinem/dgaa674
103. Rosenzweig JL, Bakris GL, Berglund LF, et al. Primary Prevention of ASCVD and T2DM in Patients at Metabolic Risk: An Endocrine Society* Clinical Practice Guideline. *J Clin Endocrinol Metab*. Jul 31 2019;doi:10.1210/jc.2019-01338
104. ASCP. American Society for Clinical Pathology. <https://www.ascp.org/content/docs/default-source/get-involved-pdfs/20-things-to-question.pdf>
105. Wong ND, Budoff MJ, Ferdinand K, et al. Atherosclerotic cardiovascular disease risk assessment: An American Society for Preventive Cardiology clinical practice statement. *Am J Prev Cardiol*. Jun 2022;10:100335. doi:10.1016/j.ajpc.2022.100335
106. NICE. Cardiovascular disease: risk assessment and reduction, including lipid modification. Updated December 14, 2023. <https://www.nice.org.uk/guidance/ng238>
107. Bibbins-Domingo K, University of California SF, Grossman DC, et al. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement. *Jama*. 2017;316(19):1997-2007. doi:10.1001/jama.2016.15450
108. Chou R, Dana T, Blazina I, Daeges M, Bougatsos C, Jeanne TL. Screening for Dyslipidemia in Younger Adults: A Systematic Review for the U.S. Preventive Services Task Force. *Annals of internal medicine*. Oct 18 2016;165(8):560-564. doi:10.7326/m16-0946
109. USPSTF. Risk assessment for cardiovascular disease with nontraditional risk factors: Us preventive services task force recommendation statement. *Jama*. 2018;320(3):272-280. doi:10.1001/jama.2018.8359
110. USPSTF. Screening for abnormal blood glucose and type 2 diabetes mellitus: U.s. preventive services task force recommendation statement. *Annals of internal medicine*. 2015;163(11):861-868. doi:10.7326/M15-2345
111. USPSTF. Screening for Cardiovascular Disease Risk With Electrocardiography: US Preventive Services Task Force Recommendation Statement. *Jama*. 2018;319(22):2308-2314. doi:10.1001/jama.2018.6848

Reimbursement Policy:

Cardiovascular Disease Risk Assessment - Lab Benefit Program (LBM)

112. Moyer VA. Screening for primary hypertension in children and adolescents: U.S. Preventive Services Task Force recommendation statement. *Annals of internal medicine*. Nov 5 2013;159(9):613-9. doi:10.7326/0003-4819-159-9-201311050-00725
113. USPSTF. High Blood Pressure in Children and Adolescents: Screening. <https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/blood-pressure-in-children-and-adolescents-hypertension-screening>
114. USPSTF. Hypertension in Adults: Screening. <https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/hypertension-in-adults-screening>
115. Pearson GJ, Thanassoulis G, Anderson TJ, et al. 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults. *Can J Cardiol*. Aug 2021;37(8):1129-1150. doi:10.1016/j.cjca.2021.03.016
116. Thompson MA, Horberg MA, Agwu AL, et al. Primary Care Guidance for Persons With Human Immunodeficiency Virus: 2020 Update by the HIV Medicine Association of the Infectious Diseases Society of America. *Clinical Infectious Diseases*. 2020;73(11):e3572-e3605. doi:10.1093/cid/ciaa1391
117. Aberg JA, Gallant JE, Ghanem KG, Emmanuel P, Zingman BS, Horberg MA. Primary Care Guidelines for the Management of Persons Infected With HIV: 2013 Update by the HIV Medicine Association of the Infectious Diseases Society of America. *Clinical Infectious Diseases*. 2014;58(1):e1-e34. doi:10.1093/cid/cit665
118. O'Malley PG, Arnold MJ, Kelley C, et al. Management of Dyslipidemia for Cardiovascular Disease Risk Reduction: Synopsis of the 2020 Updated U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline. *Annals of internal medicine*. Nov 17 2020;173(10):822-829. doi:10.7326/m20-4648

Revision History

Company(ies)	DATE	REVISION
ConnectiCare	8/2025	• Updates with effective date of 11/13/2025: ○ Coverage Criteria 3 edited to clarify that Lp(a) screening is once per lifetime AND should happen after the individual is 18 years of age ○ Coverage Criteria 4 edited to clarify that hs-CRP screening is a total of two measurements, with at least two weeks in between each one of those measurements, and that when those two tests have confirmed elevated CRP, annual measuring thereafter ○ Coverage Criteria 5 edited to define the use of both hs-CRP and conventional CRP measurement for CVD risk assessment ○ Removed 0019M, 0052U, 0308U, 0309U, 0377U and 0415U from Applicable CPT/HCPCS Procedure Codes table

Reimbursement Policy:

Cardiovascular Disease Risk Assessment - Lab Benefit Program (LBM)

Company(ies)	DATE	REVISION
ConnectiCare	8/2025	Transferred policy content to individual company-branded template. No changes to policy title or policy number.
EmblemHealth ConnectiCare	11/2024	- Updates with effective date of 3/15/2025: - Removed “to 6” from Coverage Criteria 1.a.i., now reads “i) Every 4 years for individuals ages 18 to 79 years.” - Addition of “annually” to Coverage Criteria 1.d. Now reads: “d) Annually for individuals on a long-term drug therapy that requires lipid monitoring (e.g., Accutane, anti-psychotics).”
EmblemHealth ConnectiCare	11/2023	Added CPT codes 0415U and 0019M to Applicable CPT/HCPCS Procedure Codes table with effective date of 10/1/2023
EmblemHealth ConnectiCare	8/2023	- All Coverage Criterion edited for clarity and consistency - New Note to define a simple lipid panel - Updates with effective date of 1/13/2024: - Addition of frequency to Coverage Criteria (1.b.), now allowing lipid panel screening on an annual basis for those with increased risk of dyslipidemia. - Addition of Coverage Criteria (1.i.) - Changed from Lp(a) screening only for those with risk factors to allowing once per lifetime screening of Lp(a): “3) For individuals 18 years of age or older, measurement of lipoprotein a (Lp(a)) once per lifetime MEETS COVERAGE CRITERIA.” - Addition of frequency for hs-CRP measurement in Coverage Criteria 4 - In Coverage Criteria 5, change of “situations” to “cardiovascular disease risk assessments”, “hs-CRP” changed to CRP, as no form of CRP (conventional or hs-CRP testing) should be allowed for situations not described in Coverage Criteria 4. - CPT codes 86140 and 0377U added to Applicable CPT/HCPCS Procedure Codes table



Reimbursement Policy:

Cardiovascular Disease Risk Assessment - Lab Benefit Program (LBM)

Company(ies)	DATE	REVISION
		○ Removal of CPT code 84512 from Applicable CPT/HCPCS Procedure Codes table
EmblemHealth ConnectiCare	11/2022	● Reformatted and reorganized policy, transferred content to new template with new Reimbursement Policy Number